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ABSTRACT 
The use of oral fluid for the assessment of health and diagnosis of disease in humans and 
animals has a surprisingly long history.  Early investigators attempted to evaluate metabolic 
diseases in humans by testing oral fluid for a variety of analytes, e.g., glycogen, crystal salts, 
and acid salts.  This early work led to the conclusion that the "principals" present in serum 
were also present in saliva.  As early as 1909, sensitive and specific agglutination of 
"Micrococcus melitensis" (Brucella melitensis) by oral fluid from patients diagnosed with 
Malta Fever was reported, thereby, indirectly demonstrating the presence of antibody in 
saliva.  After these early reports, developments in oral fluid diagnostics were generally 
overshadowed by technical improvements in the detection of analytes in blood or serum.  
This began to change following a report of the detection of antibodies against human 
immunodeficiency virus (HIV) in oral fluid from patients with acquired immunodeficiency 
syndrome (AIDS).  Because of this report and/or because of concurrent advances in 
diagnostic technology, oral fluid-based assays for a wide range of infectious and non-
infectious diseases, drugs, hormones, and disease markers have been developed and 
implemented in the last two decades. 
The objective of the first study was to determine whether PRRSV and/or anti-PRRSV 
antibodies were present in oral fluids at diagnostic levels. The level and duration of PRRSV 
and anti-PRRSV antibodies in serum and oral fluids was evaluated in three age groups of 
pigs (4, 8, or 12 weeks of age) inoculated with a type 2 (North American) PRRSV isolate. 
Serum, buccal swabs, and pen-based oral fluid samples were collected for 63 days following 
inoculation. Specimens were assayed for PRRSV by real-time quantitative reverse 
transcription polymerase chain reaction (qRT-PCR), and for anti-PRRSV antibodies by 
enzyme-linked immunosorbent assay (ELISA) and indirect fluorescent antibody (IFA). 
PRRSV was detected by real-time qRT-PCR in serum for approximately 5 weeks and in oral 
fluids for approximately 4 weeks postinoculation. Pig age at the time of inoculation had no 
effect on the quantity or duration of virus in oral fluid samples. Low levels of anti-PRRSV 
antibody were detected in oral fluid samples by ELISA and IFA. Although the approach 
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remains to be validated in the field, the results of this experiment suggest that pen-based oral 
fluid sampling could be an efficient, cost-effective approach to PRRSV surveillance in swine 
populations. 
The objective of the second study was to validate the use of oral fluids to detect infections 
with porcine respiratory and reproductive syndrome virus (PRRSV) and porcine circovirus 
type 2 (PCV2) in three commercial swine herds.  Oral-fluid and serum samples were 
collected from one barn on each of three PRRSV-infected finishing sites. Six pens per barn 
(20 to 30 pigs per pen) were sampled repeatedly, beginning when the pigs entered the 
facilities (3 weeks of age), and then at 5, 8, 12, and 16 weeks of age. Serum samples were 
tested using a commercial PRRS ELISA. Both serum and oral-fluid samples were tested for 
PRRSV by quantitative reverse-transcriptase polymerase chain reaction (PCR), and oral 
fluids were tested for PCV2 by qRT-PCR.  Site One pigs seroconverted to PRRSV at 12 
weeks of age, and Site Two and Three pigs at 5 to 8 weeks of age. All individual serum 
samples tested PCR-negative for PRRSV in pigs 3 to 5 weeks old, while > 1 sample tested 
positive in pigs 8, 12, and 16 weeks old, with 77% agreement between oral-fluid and serum 
pen-level results. At all sites, > 1 oral-fluid sample tested PCR-positive for PCV2 beginning 
when pigs were 8 weeks old.  Oral-fluid samples may be used to monitor PRRSV and PCV2 
infections in commercial production systems. PRRSV virus is detectable in oral fluids for 3 
to 8 weeks, and PCV2 may be detectable for > 8 weeks. Sampling at 2- to 4-week intervals is 
recommended for surveillance of PRRSV and PCV2.  
The objective of the third study was to evaluate the stability of porcine reproductive and 
respiratory syndrome virus (PRRSV) and anti-PRRSV antibodies in oral fluid as a function 
of time and temperature.  A 4-liter pool of swine oral fluid was collected from 16-week old 
finisher pigs. To ensure uniform, quantifiable levels of virus and antibody over time, the pool 
was “spiked” with 4 ml of PRRSV isolate ISU-P containing 1 x 1012 RNA copies per ml and 
10 ml of concentrated hyper-immune anti-PRRSV antibodies.  The pool was divided into 3 
equal portions: (1) no treatment; (2) chlorhexidine digluconate at 0.01% by volume; (3) 
isothiazolinone at 3 parts per million.  Each treatment was run in triplicate at each of five 
temperatures (-20°C, 4°C, 10°C, 20°C, 30°C).  Samples were removed at specific intervals (0 
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hr, 12 hr, 24 hr, 48 hr, 72 hr, 144 hr, 216 hr, and 288 hr), stored at -80ºC, and then assayed 
for: (1) PRRSV RNA; (2) IgM, IgA, and IgG; (3) ELISA-detectable PRRSV-specific 
antibody; (4) culturable bacteria per ml.   The results showed that the stability of anti-PRRSV 
antibody and PCR-detectable PRRSV was highly temperature-dependent, with antimicrobial 
treatment providing no improvements in stability at lower temperatures.  In particular, both 
virus and antibody were stable at ≤ 10°C over 12 days of storage.  Conventional serum 
storage protocols (freezing or refrigeration at 4°C) will preserve PRRSV and anti-PRRSV 
antibody in oral fluid diagnostic samples. 
The objective of the fourth study was to evaluate the onset, level, and duration of quantitative 
polymerase chain reaction-detectable PCV2 and anti-PCV2 antibody in oral fluid was 
evaluated using samples collected from experimentally-inoculated pigs for 98 days post 
inoculation (DPI).  Pigs (n = 24) were obtained at 3 weeks of age and randomly allocated to 4 
treatment pens of 6 pigs each:  (1) negative control group;  (2) inoculated with PCV2a (strain 
ISU 40895) on DPI 0;  (3) inoculated with PCV2a (strain ISU-40895) on DPI 0 and re-
challenged at DPIs 35 and 70;  (4) inoculated with PCV2a (ISU-40895), PCV2b (PVG4072), 
and PCV2a (ISU-4838) on DPIs 0, 35, and 70, respectively.  Serum was collected from each 
animal and one oral fluid sample was collected from each pen (group) every other day from 
DPI 2 through DPI 14 and weekly through 98 DPI.  Oral fluid samples were assayed for the 
presence of PCV2 by PCR, anti-PCV2 IgG antibody by enzyme linked immunosorbent assay 
(ELISA), and anti-PCV2 antibody isotypes (IgA, and IgM) by ELISA.  Serum was assayed 
for anti-PCV2 IgG by ELISA.  Anti-PCV2 antibodies (IgG, IgM, and IgA) were detected in 
oral fluid from experimentally inoculated pigs from 14 to 98 DPI.  PCV2 was detected by 
PCR in oral fluid samples from all pens of inoculated pigs at 2 DPI.  Thereafter, PCV2 was 
detected in oral fluid throughout DPI 98.  Overall, the data indicated that PCV2 infection in 
swine populations can be efficiently monitored using oral fluid specimens.  
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DISSERTATION ORGANIZATION 
This dissertation consists of five chapters.  Chapter 1 is the general introduction and review 
of the literature, “The development of oral fluid-based diagnostics and applications in 
veterinary medicine”.  Chapter 2, “Detection of porcine reproductive and respiratory 
syndrome virus infection in porcine oral fluid samples: a longitudinal study under 
experimental conditions” is published in the Journal of Veterinary Diagnostic Investigation.  
Chapter 3, “Surveillance of commercial growing pigs for porcine reproductive and 
respiratory syndrome virus and porcine circovirus type 2 infections using oral fluid samples” 
is published in the Journal of Swine Health and Production.  Chapter 4, Stability of PCR-
detectable PRRSV and anti-PRRSV antibody in swine oral fluid spiked with PRRSV and 
anti-PRRSV antibody” is submitted for publication in the Journal of Swine Health and 
Production.  Chapter 5, “Prolonged detection of PCV2 and anti-PCV2 antibody in oral fluids 
following experimental inoculation” is in preparation for submission to Veterinary Research.  
References, tables, and figures for each research manuscript follow the discussion section of 
each.  The last chapter contains the general conclusions of the dissertation research. 
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CHAPTER 1. THE DEVELOPMENT OF ORAL FLUID-BASED DIAGNOSTICS 
AND APPLICATIONS IN VETERINARY MEDICINE 
 
For submission to Animal Health Research Reviews 
John Prickett 
 
"Saliva is not one of the popular bodily fluids.  It lacks the drama of blood, the sincerity of 
sweat and the emotional appeal of tears."  Irwin D. Mandel (1990) 
Introduction 
The purpose of this review is to summarize the history of the development and 
implementation of oral fluid diagnostics for infectious diseases of human and domestic 
animals.  The use of oral fluid for the assessment of health and diagnosis of disease in 
humans and animals has a surprisingly long history.  Early investigators attempted to 
evaluate metabolic diseases in humans by testing oral fluid for a variety of analytes, e.g., 
glycogen, crystal salts, and acid salts (Michaels, 1901).  This early work led to the conclusion 
that the "principals" present in serum were also present in saliva.  As early as 1909, Pollaci 
and Ceraulo reported sensitive and specific agglutination of "Micrococcus melitensis" 
(Brucella melitensis) by oral fluid from patients diagnosed with Malta Fever, thereby, 
indirectly demonstrating the presence of antibody in saliva.  After these early reports, 
developments in oral fluid diagnostics were generally overshadowed by technical 
improvements in the detection of analytes in blood or serum.  This began to change following 
a report of the detection of antibodies against human immunodeficiency virus (HIV) in oral 
fluid from patients with acquired immunodeficiency syndrome (AIDS) (Archibald et al., 
1986).  Because of this report and/or because of concurrent advances in diagnostic 
technology, oral fluid-based assays for a wide range of infectious and non-infectious 
diseases, drugs, hormones, and disease markers have been developed and implemented in the 
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last two decades (Mandel, 1993; Tabak, 2007). 
Basic concepts 
The fluid in the oral cavity consists of saliva and transudates originating from the circulatory 
system.  The major salivary glands of mammals vary in number, structure, location, and size 
(Shackleford and Wilborn, 1968), but humans and the domestic animals (cat, dog, pig, 
ruminants, horse) all possess at least three major salivary glands, as well as numerous minor 
salivary glands.  Humans possess parotid, submandibular, and sublingual glands (Navazesh, 
1993); equines and swine have parotid, mandibular, and sublingual glands (Sisson, 1975a, 
1975b); ruminants have four glands, i.e., the parotid, mandibular, monostomatic sublingual, 
and polystomatic sublingual glands (Habel, 1975); the dog and cat have parotid, mandibular, 
sublingual, and zygomatic, glands, with the cat also possessing two well-developed molar 
salivary glands (Wiggs and Lobrise, 1997). 
The composition of saliva varies among salivary glands, but regardless of species, saliva is 
mostly water in which are suspended a myriad of molecules with important biological 
functions, e.g., mucin, amylase, lysozyme, lipase, and proline-rich glycoproteins.  Within the 
oral cavity, saliva and its constituents perform important functions related to lubrication, anti-
microbial activity, cleansing, bolus formation, mastication, digestion, taste, tooth 
remineralization, and phonation (Llena-Puy, 2006). 
In addition to saliva, the fluid in the oral cavity contains serum transudate that crosses the 
oral mucosa (oral mucosal transudate) and gingiva (gingival crevicular fluid) from capillaries 
located in the oral mucosa and the gingival tissues (Cameron and Carman, 2005; Delima and 
Van Dyke, 2003).  The process of passive transudation was first demonstrated by 
intravenously injecting fluorescein dye into the hind leg of dogs (n = 6) and recording 
fluorescence on filter paper strips collected within and at the gingival crevice (Brill and 
Krasse, 1958).  In these experiments, the dye appeared at the gingival crevice within 30 
seconds after injection, but within 60 minutes had not appeared in the eye, hard palate, floor 
of the mouth, buccal, or labial mucosal, tongue, alveolar mucosa, nasal cavity, rectum, or 
vagina.  The authors proposed that antibodies reached the oral cavity from serum via the 
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gingival crevice and served a protective role in the mouth.  This experiment was followed by 
similar work in which humans ingested fluorescein dye capsules (Brill and Björn, 1959).  
Similar results were reported, with the addition of fluorescein dye appearing in more tissues 
than was seen in dogs, i.e., nasal mucous membranes.  Passive transfer of virus from serum 
to oral fluid was demonstrated with Coxsackie B-1 virus.  Rabbits were intravenously 
injected with Coxsackie B-1 virus (Madoniaet al., 1966) and the virus was detected in oral 
fluid samples 2 minutes post-injection at concentrations of 1 x 104 median tissue culture 
infectious dose (TCID50) per 0.1 ml or greater.  As a result of these experiments, the 
connection between the circulatory system and the oral cavity was identified.  Subsequent 
work established that the fluid in the oral cavity also reflected the concentration of hormones, 
drugs, antibodies, viruses, and other components in serum (Mandel, 1993). 
In the context of this review of diagnostic applications, it is important to be aware that the 
composition of fluid from the oral cavity is markedly affected by the method of collection 
(stimulated vs. unstimulated), collection device (Chang et al., 2009), and/or the site of sample 
collection within the oral cavity (Atkinson et al., 1993).  Atkinson et al. (1993) define "oral 
fluid" as the fluid in the oral cavity collected by use of an absorptive device.  This describes 
the process and the method most commonly used to collect diagnostic samples.  Therefore, 
"oral fluid" will be used in this sense for the remainder of this review. 
Historical developments leading to oral fluid diagnostics 
Beginning with the work of Pollaci and Ceraulo in 1909, evidence for the presence of 
antibodies in oral fluid accumulated slowly over the first half of the 20th century.  Antibodies 
against Treponema pallidum were demonstrated in oral fluid in 1940 (Kanter and Appleton, 
1940) and again in 1953 (Coleman and Appleman, 1953).  Citing the work of Pollaci and 
Ceraulo (1909) and Coleman and Appleman (1953), Wheatcroft (1957) analyzed matched 
serum and oral fluid samples from persons infected with Brucella melitensis and 
demonstrated a correlation (r = 0.674) between serum antibody complement fixation titers 
and oral fluid bacterial agglutination titers.  
The presence of serum proteins in human oral fluid was demonstrated in 1960 (Ellison et al., 
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1960).  Kraus and Konno (1963) showed that antibody was only present in oral fluid when it 
was present in the serum of the same individual, concluding that this was evidence of a 
"selective and individually regulated transfer of serum proteins into saliva."  This would later 
prove to be partially true, but would not fully account for all of the antibody in oral fluid. 
By 1963 (Kraus and Konno, 1963), independent research had demonstrated the presence of 
antibody and/or antigen in human oral fluid from patients infected with a variety of 
pathogens.  Investigators had repeatedly commented on the consistently lower concentration 
of antibody in oral fluid when compared to matched serum samples and had expressed 
concern about the impact of lower antibody concentration on the diagnostic sensitivity of 
antibody-based assays.  Three concepts were common to the research literature of the time: 
(1) the absence of oral fluid reactions in seronegative subjects;  (2) lower antibody titers in 
oral fluid vs. matched serum samples; and  (3) the inconsistent results of oral fluid samples 
from seropositive subjects.  
By 1964, five antibody isotypes (IgM, IgG, IgA, IgD, IgE) had been identified in humans 
(Martin 1969) and it had became evident that IgA was the predominant isotype present in 
oral fluid (Tomasi and Ziegelbaum, 1963).  The identification of a secretory component in 
conjunction with IgA (South et al., 1966) and IgM (Brandtzaeg, 1975) provided evidence for 
local production of antibody. 
Sources of oral fluid antibodies  
Definitive evidence of the passage of serum antibody (IgG, IgM, IgA) from the circulatory 
system into the oral cavity was reported by Challacombe et al. in 1978 using rhesus 
monkeys.  Specifically, intravenously injected radio-labeled IgG, IgM, and IgA was detected 
in oral fluid 30 minutes later (first sampling point).  This simple experiment demonstrated the 
transfer of serum-derived antibody into oral fluid. 
Local production of antibody by serum-derived plasma cells in salivary glands and duct-
associated lymphoid tissue (DALT) was also described during this period (Beckenkamp, 
1985; Brandtzaeg, 1981, 1989; Crawford et al., 1975; Mestecky 1987, 1993; Morrier and 
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Barsotti, 1990; Nair and Schoeder, 1986).  These cells secreted IgA into saliva in conjunction 
with ductal and actinar epithelial cells expressing receptors specific for IgA.  In humans, 
minor salivary glands (MSG) were also demonstrated to play a substantial role in IgA 
production, contributing 30 to 35% of total IgA in response to local antigenic stimulae 
(Crawford et al., 1975).  IgM and IgG were also found to be locally secreted, but at lower 
concentrations than IgA (Challacombe et al., 1995).  Corroborative data from other species 
supported these initial observations.  For example, immune responses in the local tissues of 
the nasal and oral cavities were examined in mice orally immunized with biodegradable 
microparticles and IgA-secreting cells were demonstrated in salivary glands and nasal-
associated lymphoid tissue (NALT) by ELISPOT assays and the secreted antibody was 
demonstrated in oral fluid by ELISA at all sampling points post-inoculation (Challacombe et 
al., 1997). 
Oral fluid diagnostics in human medicine 
The conclusive demonstration of systemic and locally produced antibody (IgA, IgM, IgG) in 
oral fluid suggested its possible use as a diagnostic specimen for infectious diseases, but the 
report that precipitated the development of oral fluid diagnostics was the isolation of human 
t-cell leukemia virus type III (HTLV-III, later renamed human immunodeficiency virus) from 
oral fluid collected from people with AIDS (Groopman et al., 1984).  By 1986, antibodies 
against HTLV-III were demonstrated in patients with AIDS and/or their sexual partners 
(Archibald et al., 1986).  This pivotal publication suggested that detection of clinically 
healthy individuals infected with HTLV-III could be achieved using oral fluid specimens 
instead of serum.  This concept was quickly evaluated and pre-clinical trials on 600 
individuals reported that oral fluid and serum results were equivalent (Schaefer, 1990).  In 
1990, the Food and Drug Administration (FDA) approved clinical trials for the comparison 
of a commercial oral fluid collection device at five sites within the U.S. (Schaefer, 1990) and 
in 1994, the FDA approved the first oral fluid collection kit for the detection HIV antibody 
(Nightingale, 1995). 
Development of HIV detection technology continued speedily and in the period 2002 to 2006 
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the FDA approved four rapid HIV assays designed to detect antibodies in oral fluid 
specimens (Branson, 2007).  Based on the data submitted for FDA approval, the first 
approved test (OraQuick® Rapid HIV-1 Antibody Test; OraSure Technologies, Inc., 
Bethlehem, PA) was estimated to have a diagnostic sensitivity of 99.6% (95% CI = 98.5%, 
99.9%) and specificity of 100% (95% CI = 99.7%, 100%).  An evaluation of the second 
generation assay (OraQuick® Advance Rapid HIV-1/2 Antibody Test; OraSure 
Technologies, Inc., Bethlehem, PA) reported a remarkably low false-positive rate of 
0.27%.based on 166,058 tests performed between March 2005 and May 2008 at 10 New 
York City Sexually Transmitted Diseases (STD) clinics (Rothman and Kalish, 2009).  False-
positive results were determined by performing Western Blot analysis on serum samples 
from individuals with positive oral fluid screening results. 
In human diagnostic medicine, a plethora of publications describing the development and 
application of oral fluid assays for HIV detection may be found in the literature, but the 
application of oral fluid diagnostics for pathogens and/or antibody have been described for 
several other infectious diseases (Table 1).  Oral fluid offers some distinct advantages over 
serum-based testing.  In particular, specimens are easily collected by personnel with minimal 
technical training, or even by patients in their homes, and samples are easily processed and 
stored (Chiappin et al., 2007).  As a result, oral fluid-based testing has facilitated the 
collection of large amounts of epidemiological data on significant infectious agents, e.g., 
HIV in Africa (Connolly et al., 2004; Fylkesnes and Kasumba, 1998) and Thailand (Frerichs 
et al., 1994) and measles in Europe (Ramsay et al., 1997), Ethiopia (Nigatu et al., 2008), 
Brazil (de Azevedo Neto et al., 1995; Oliveira et al., 1998), and Africa (Ohuma et al., 2009). 
Oral fluid diagnostics in veterinary medicine 
The literature describing the detection of antibodies and pathogens in oral fluid of 
domesticated mammals describes core findings similar to those reported in human research.  
For simplicity, the veterinary research section of the review is organized by species. 
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Feline 
Detection of antibodies in oral fluid          Harley et al., (1998) developed ELISA methods 
to quantify feline immunoglobulins in oral fluid and characterized the levels of IgG, IgM, 
and IgA in stimulated and non-stimulated oral fluid collected from healthy cats in 12 hour 
intervals for 4 days.  They reported that oral fluid was most rich in IgA, stimulated oral fluid 
contained a lower concentration of immunoglobulin, and the concentration of 
immunoglobulin in oral fluid was generally consistent across multiple sampling points.  
Detection of pathogens in oral fluid          The detection of feline leukemia virus (FeLV) 
antigen in feline oral fluids was first reported in the late 1980's (Lewis et al., 1987; Lutz and 
Jarrett, 1987) and oral fluid antigen tests are commercially available and commonly used to 
screen for FeLV infection.  Recent publications have reported the detection of FeLV RNA in 
oral fluid by PCR compared to the antigen ELISA routinely used in veterinary clinics 
(Gomes-Keller et al., 2006a,b).  They reported excellent diagnostic performance and close 
agreement between PCR and antigen capture ELISA results. 
Feline immunodeficiency virus (FIV) was first demonstrated in oral fluid collected from 
inoculated cats in 1988 (Yamamoto et al., 1988).  Subsequently, Poli et al., (1992) 
demonstrated detectable anti-FIV IgG in oral fluid samples collected from 15 of 16 
seropositive cats and 0 of 16 seronegative cats.  Anti-FIV IgA was also detected in oral fluid 
from 13 of 16 seropositive cats and 0 of 16 seronegative cats. 
In addition to feline retroviruses, PCR detection of Candidatus Mycoplasma turicensis’ 
(CMt) in oral fluid from cats was reported by Willi et al. (2006).  Dean et al. (2007) 
corroborated the original report and also detected Mycoplasma haemofelis (Mhf) and 
Candidatus Mycoplasma haemominutum (CMhm) in oral fluid.  
Canine 
Detection of antibodies in oral fluid          Immunoglobulins in canine oral fluid have been 
described by Heddle and Rowley (1975) and in greater detail by German et al., 1998.  As in 
other species, canines produce local IgA and IgM, but oral fluid also contains serum-derived 
IgG and albumin.  German et al. (1998) found little variation in total immunoglobulin 
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concentration between multiple oral fluid samples collected from the same animal over time.  
In dogs experimentally challenged with Taenia pisiformis, specific IgG and IgA was detectable 
for 12 weeks post-inoculation, the end of the study (Kinder et al., 1992).  The authors suggested 
oral fluid specimens could serve as an alternate method of detecting intestinal helminth infection 
and replace the traditional, but relatively diagnostically insensitive, process of detecting proglottides 
or eggs in fecal samples. 
Detection of pathogens in oral fluid          Of public health interest, some zoonotic 
pathogens are detectable in canine oral fluid.  Rabies virus is commonly transmitted via 
animal bites and has been demonstrated in canine oral fluid (Côrtes et al., 1979; Fekadu et 
al., 1982; Kasempimolporn et al., 2000).  Several strains of Bartonella spp. have been 
detected in canine saliva by PCR (Duncan et al., 2007). 
Equine and Ovine 
In equines, local production of immunoglobulins in parotid and submandibular salivary 
glands has been demonstrated (Genco et al., 1969; Hurlimann and Darling, 1971).  In sheep, 
IgA is the major immunoglobulin in oral fluid (Smith et al., 1975).  Experiments using radio-
labeled iodine demonstrated that the majority of IgA in sheep oral fluid is of local origin, 
with IgM selectively transported into respiratory secretions and saliva (Scicchitano et al., 
1986).  Diagnostically, equine oral fluid has been used to test for the presence of 
performance altering chemicals in race horses (Homer, 1976; Morgan and Gellhorn, 1947), 
but no reports of the use of oral fluid for the detection of infectious diseases were found for 
equines or ovines.  
Bovine 
While oral fluid samples have been used to isolate and culture bacterial pathogens (E. coli 
and Salmonella) from feedlot cattle (Smith et al., 2004, 2005; Renter et al., 2004; Standford 
et al., 2005), the detection of foot-and-mouth disease virus (FMDV) has been the major focus 
of research in bovines.  The earliest work on oral fluid reported the presence of anti-FMDV 
neutralizing antibody, presumably locally produced, in calves following nasal inoculation 
with live type 01 FMDV (Figueroa et al., 1973).  Archetti et al., (1995) measured total anti-
FMDV immunoglobulin and IgA in oral fluid and probang (oropharyngeal fluid) samples of 
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vaccinated or FMDV-infected animals.  Vaccinated cattle did not generate an antibody 
response detectable in either sample type, but cattle exposed to, or inoculated with, live 
vaccine produced detectable IgA in oral fluid.  Later work led to the concept that secretory 
IgA in oral fluid may be used to differentiate vaccinated from FMDV-infected animals 
(Parida et al., 2006).  Parida et al. (2006) developed an ELISA to detect IgA antibody against 
non-structural proteins (NSP) in oral fluid under the premise that vaccines used in response 
to an FMDV outbreak would not include NSPs.  Considering their work preliminary, they 
reported a diagnostic specificity of 99.4% and suggested a potential application for detecting 
persistently infected, sub-clinically infected, or vaccinated animals. 
Porcine 
Detection of antibodies in oral fluid          The first report of antibodies in oral fluid from 
pigs was published in 1976 when Corthier (1976) reported that intranasal vaccination of pigs 
with the Thiverval strain of classical swine fever virus (CSFV) resulted in detectable 
antibody in pharyngeal secretions.  They subsequently inoculated pigs via intranasal and 
intramuscular routes and measured the antibody response in serum and oral fluid (Corthier 
and Aynaud, 1977).  Strong responses were measured in both sample types, indicating both 
systemic and local immune responses.  The strongest local response (in oral fluid) was 
observed after intranasal inoculation at the highest dose used. 
DeBuysscher and Dubois (1978) inoculated pigs with E. coli strain 1261 via oral or Thiry-
Vella loop routes and examined the submandibular and sublingual salivary glands post 
mortem by staining for anti-E.coli plasma cells of the IgA, IgM, and IgG isotypes.  They 
reported IgA-secreting plasma cells to be most numerous followed by approximately equal 
numbers of IgM- and IgG-secreting cells, but found no significant differences in the number 
and isotype of plasma cells in submandibular and sublingual salivary glands between pigs 
orally or Thiry-Vella loop inoculated pigs. 
A few years later DeBuysscher and Berman (1980) performed essentially the same 
experiment, but with transmissible gastroenteritis virus (TGEV).  They observed substantial 
increases in the number of IgA-secreting cells in salivary glands, followed by IgM-secreting 
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cells, and a small increase in the number of IgG-secreting cells in both orally and Thiry-Vella 
loop inoculated pigs.  These findings supported the conclusion that corollary increases in 
antigen-specific plasma cells in intestinal mucosa and distant secretory tissues, i.e., salivary 
glands, result from the secretory component receptor-conveyor mechanism. 
Loftager et al. (1993) collected samples from pigs intranasally inoculated with Actinobacillus 
pleuropneumoniae (APP) and pigs naturally infected with APP.  IgA concentrations in oral 
fluid and serum collected over time were measured using a whole-cell ELISA.  IgA was 
detectable in oral fluid before it appeared in serum and declined more rapidly than serum IgA 
or IgG.  These investigators concluded that oral fluid IgA detection could serve as a practical 
method to screen for early infection with APP. 
Detection of pathogens in oral fluid          Several swine pathogens are known to be present 
in detectable levels in oral fluid samples.  Vesicular stomatitis virus (VSV) has been isolated 
from oral fluid, but not serum, from pigs infected via mechanical vectors or by direct contact 
with infected pigs (Stallnecht et al., 1999).  In pigs inoculated with FMDV (O TAW 3/97), 
virus was recovered by virus isolation for up to 10 DPI and by PCR for up to 11 DPI (Eblé et 
al., 2004).  Recently, the detection of porcine respiratory and reproductive syndrome virus 
(PPRSV) and porcine circovirus type 2 (PCV2) was reported in swine oral fluid samples 
collected under both experimental and field conditions (Prickett et al., 2008a,b). 
Future applications of oral fluid diagnostics in veterinary medicine 
Cumulatively, the literature strongly supports implementation of oral fluid-based diagnostics.  
Pathogen-specific IgA, IgM, and IgG antibodies have all been demonstrated in oral fluid 
collected from diverse domestic animal species in response to infection.  A variety of 
infectious agents, both local and systemic, are shed in oral fluid, including some of the most 
economically significant pathogens of production animals, e.g., FMDV, CSFV, and PRRSV.  
From the perspective of animal welfare, oral fluid sampling also offers a more "animal 
friendly", non-invasive method to collect diagnostic specimens.  Taken together, the 
diagnostic properties of oral fluid present an opportunity to formulate diagnostically sensitive 
and specific oral fluid-based assays. 
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Application of oral fluid-based testing facilitates monitoring, surveillance, and detection of 
disease in animal populations.  For example, despite our best efforts, PRRSV, M. 
hyopneumoniae, influenza, PCV2, and other endemic pathogens continue to cause significant 
economic losses in large U.S. swine production systems (Holtkamp D, Rotto H, Garcia R.  
2007.  The economic cost of major health challenges in large U.S. swine production systems.  
Proc 2007 American Association of Swine Veterinarians Annual Meeting.  Orlando, Florida, 
pp. 85-89).  In part, the disease status quo is maintained by the lack of timely information on 
the circulation of pathogens.  Oral fluid testing offers an opportunity to easily collect herd-
level disease data on a periodic basis.  Integration of longitudinal disease data with herd 
records (interventions, morbidity, mortality, and production parameters) would provide for  
(1) appropriately timed and targeted interventions;  (2) "real time" evaluations of 
interventions; and  (3) improved, herd-specific estimates of the impact of specific pathogens 
on pig health and productivity.  This proactive approach to disease monitoring translates 
diagnostic costs into improved growth performance rather than a historical vignette of past 
disease events. 
Once established for the routine management of endemic diseases, an oral fluid surveillance 
infrastructure would facilitate rapid data collection in situations such as regional or national 
disease control and/or eradication programs or foreign animal disease (FAD) contingency 
efforts.  Collection of diagnostic specimens by on-site personnel would profoundly impact 
the time to detection and effectiveness of control of FAD outbreaks. 
The purpose of this review was to summarize the history of the development and 
implementation of oral fluid diagnostics for infectious diseases of human and domestic 
animals.  A tangential objective is to promote research in diagnostic applications of oral fluid 
in veterinary medicine, with the hope that animal health can eventually realize the benefits 
offered by oral fluid diagnostics.  At this point, research is necessary to develop and 
standardize collection methods, optimize diagnostic assays for the oral fluid specimens, and 
establish sampling protocols for pathogens of interest.  Ultimately, point-of-care rapid assays, 
i.e., cow-side, sow-side, or pen-side tests, will revolutionize our delivery of health 
management services.  
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Tables 
Table 1. Selected examples of diagnostic applications for the detection of infectious diseases 
of humans based on oral fluid specimens 
Pathogen Target analyte Citation 
Bordetella pertussis IgG Litt et al., 2006 
Coronavirus  virus (PCR) Wang et al., 2004 
Cryptosporidium parvum  IgG Moss et al., 2004 
Cytomegalovirus  IgG, IgA Hochman et al., 1998 
Dengue virus  IgG, IgM Cuzzubbo et al., 1998 
Diphtheria toxoid  IgG, IgA Newcomb et al., 1969 
Ebola virus IgG, PCR Formenty et el., 2006 
Epstein-bar virus  IgG, IgA Hochman et al., 1998 
Hantaan virus  IgG, IgM Petraityte et al., 2007 
Helicobacter pylori  IgG Luzza et al., 1995 
Hepatitis A, B, C  IgM Amado et al., 2006 
Human herpes virus type 1 virus (PCR) Scott et al., 1997 
Human herpes virus type 6  virus (PCR) Collot et al., 2002 
Human leptospirosis  IgM da Silva et al., 1992 
Infuenza virus  IgA Waldman, 1968 
Japanese encephalitis IgG, IgM, IgA Prasad et al., 1994 
Measles  IgM Brown et al., 1994 
Mumps  Neutralizing antibody Chiba and Nakao, 1972 
Mumps  IgM Frankova and Sixtova, 1987 
Norwalk virus  IgG, IgA Moe et al., 2004 
Polio virus  IgA Berger, et a., 1967 
Rotavirus  IgA Ward et al., 1992 
Rubella  IgG Ben Salah et al., 2003 
Salmonella tyhpi  IgA Herath, 2003 
Treponema pallidum IgG Baguley et al., 2005 
Trypanosoma cruzi  IgG Pinho et al., 1999 
Varicella-zoster virus  virus (PCR) Furuta et al., 2004 
Yersinaia entercolitica IgG Grönblad and Mäkelä,1986 
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Abstract 
Isolation of porcine reproductive and respiratory syndrome virus (PRRSV) from oral fluids 
was first reported in 1997.  The objective of the present study was to determine whether 
PRRSV and/or anti-PRRSV antibodies were present in oral fluids at diagnostic levels.  The 
level and duration of PRRSV and anti-PRRSV antibodies in serum and oral fluids was 
evaluated in three age groups of pigs (4, 8, or 12 weeks of age) inoculated with a type 2 
(North American) PRRSV isolate.  Serum, buccal swabs, and pen-based oral fluid samples 
were collected for 63 days following inoculation.  Specimens were assayed for PRRSV by 
real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), and for 
anti-PRRSV antibodies by enzyme-linked immunosorbent assay (ELISA) and indirect 
fluorescent antibody (IFA).  PRRSV was detected by real-time qRT-PCR in serum for 
approximately 5 weeks and in oral fluids for approximately 4 weeks postinoculation.  Pig age 
at the time of inoculation had no effect on the quantity or duration of virus in oral fluid 
samples.  Low levels of anti-PRRSV antibody were detected in oral fluid samples by ELISA 
and IFA.  Although the approach remains to be validated in the field, the results of this 
experiment suggest that pen-based oral fluid sampling could be an efficient, cost-effective 
approach to PRRSV surveillance in swine populations. 
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Introduction 
‘Oral fluid’ is a mixture of saliva and mucosal transudate.  Saliva is produced by the parotid, 
submandibular, and sublingual salivary glands, as well as the minor salivary glands located 
on the lips, tongue, palate, cheeks, and pharynx.14 Mucosal transudates originate from the 
gingival and buccal mucosa and contain serum-derived antibodies.24 
The presence of porcine reproductive and respiratory syndrome virus (PRRSV) in oral fluids 
was first reported in 1997.36  Virus was isolated from buccal swabs collected from 
experimentally-inoculated young pigs on 7, 14, 21, 28, 35, and 42 days postinoculation 
(DPI).  The isolation of PRRSV was also reported from oropharyngeal (“tonsil scraping”) 
samples.37 Virus was recovered from 3 of 4 pigs sampled on 56, 70, and 84 DPI, and one pig 
sampled on 157 DPI.  These reports suggested the possibility that porcine oral fluid samples 
could be used to monitor PRRSV infection.  The purpose of the present study was to 
determine if PRRSV and/or anti-PRRSV antibodies were present in oral fluids at consistently 
detectable levels and, if so, how long PRRSV and/or anti-PRRSV antibodies were present in 
oral fluids and whether this was affected by pig age. 
Materials and Methods 
Experimental design 
The level and duration of PRRSV and anti-PRRSV antibodies in serum and oral fluids was 
evaluated in three age groups of pigs (4, 8, or 12 weeks of age at time of inoculation).  Each 
age group consisted of 16 pigs (12 PRRSV-inoculated, 4 negative controls) housed in pens of 
four pigs each, with the exception of 4-week-old PRRSV-inoculated pigs, which were housed 
in two pens of six pigs each.  Pigs were randomly assigned to treatment groups.  Serum 
samples collected 8 days before the start of the experiment and day 0 were assayed by 
enzyme-linked immunosorbent assay (ELISA) to confirm the absence of PRRSV infection.  
The pigs were intramuscularly inoculated on day 0 with 2 ml of a preparation containing 1 x 
101.7 50% tissue culture infective dose (TCID50) of PRRSV per ml.  After PRRSV 
inoculation, serum, buccal swabs, and oral fluids were collected at regular intervals for 63 
days.  At the end of the experiment, all samples were randomized, relabeled, and submitted 
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for testing.  Samples were assayed for the presence of PRRSV by real-time quantitative 
reverse transcription polymerase chain reaction (qRT-PCR) and for the presence of anti-
PRRSV antibodies by ELISA and indirect fluorescent antibody (IFA) assay. 
Animals and animal care 
Pigs were obtained from a commercial swine herd1 known to be free of PRRSV.  Pigs were 
received at 3, 7, or 11 weeks of age and housed in the Livestock Infectious Disease Isolation 
Facility, College of Veterinary Medicine, Iowa State University (Ames, IA).  Animals were 
housed on the floor in pens that were cleaned daily.  Feeder space, square footage per animal, 
ambient temperature, and room air exchanges all met or exceeded guidelines and 
requirements set forth in the Guide for the Care and Use of Agricultural Animals in 
Agricultural Research and Teaching.8  Animals were fed ad libitum an age-appropriate 
commercial feed that met or exceeded the nutritional requirements for swine as determined 
by the National Research Council.26 
PRRSV 
A type 2 (North American) PRRSV isolate (ISU-P) was used in this study.  The isolate was 
initially recovered from a homogenate prepared from a pool of lung tissues collected in 
October 1990 from young pigs in a herd experiencing an acute outbreak of PRRSV in 
Illinois.  As described elsewhere,39 the virus was initially isolated on porcine alveolar 
macrophage (PAM) cultures.  Subsequently, the isolate was cloned by three rounds of 
limiting dilutions in PAMs and twice by plaquing in MA-104 cells.  The working stock of 
virus used in the present study represented the fourth passage in MA-104 cells. 
Preparation of PRRSV inoculum 
The PRRSV inoculum was prepared as previously described.12 Each dilution was run in 
duplicate and the means were used to calculate the virus titer using the Spearman-Karber 
method.13 The titer of the inoculum was estimated at 1 × 101.7 TCID50 per ml. 
Collection of biological samples 
Blood samples were collected from all pigs twice weekly through 14 DPI, then weekly 
through 63 DPI.  Samples were collected using a single-use blood collection system.a Blood 
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samples were centrifuged at 1000 x g for 10 min, after which the serum was harvested and 
stored at –20°C. 
Buccal samples were collected from all pigs twice weekly through 21 DPI using polyester 
swabs.b Following collection, swabs were placed in 5-ml snap-cap tubesa containing 1 ml of 
PBS and stored at –20°C. 
Pen-based oral fluid samples were collected twice weekly through 61 DPI by suspending a 
length of 3-strand twisted cotton ropec in each pen of four or six pigs.  To facilitate oral fluid 
collection, each pen was equipped with a 90° bracket with a one inch hole in the center of the 
horizontal surface.  Brackets were fixed in place by bolting the bracket to a back plate 
through the vertical bars of the pen.  One bracket was located in each pen such that the rope 
could be placed and recovered without the need to enter the pen.  For sample collection, one 
end of the rope (1.59 cm or 1.27 cm [5/8 inch or 1/2 inch]) was knotted and the opposite 
(unknotted) end threaded through the hole in the horizontal surface of the bracket.  The rope 
was cut to length so that the end was at shoulder height to the animals.  Ropes were left in 
place for 20 to 30 min.  Pigs actively sought out and chewed the rope, leaving the strands 
moistened with oral fluids.  To recover the oral fluid sample, the bottom 30.48 cm (12 inch) 
of the rope was inserted into a 17.78 cm by 30.48 cm (7 inch by 12 inch) stomacher filter 
bagb while still suspended from the bracket and cut from the upper portion of the rope.  Oral 
fluids were extracted from the rope by mechanical compression (wringer), decanted into 5-ml 
snap-cap tubes, and stored at –20°C until assayed. 
PRRSV real-time qRT-PCR 
For purposes of comparison, oral fluid samples were submitted to two laboratories (A and B) 
for PRRSV real-time qRT-PCR analysis; serum samples only to laboratory A. 
Laboratory A.  qRT-PCR to detect and quantify PRRSV RNA (ORF7) was performed as 
previously described.11  In brief, PRRSV RNA was extracted from 0.14 ml of sample with a 
QIAamp viral RNA mini kit.d  Real-time RT-PCR was performed using an ABI Prism 7900 
HT sequence detection systeme using oligonucleotide primersf and minor groove binder 
(MGB) probese specific for ORF7.  The thermal profile for amplification of PRRSV viral 
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RNA was a reverse transcription at 50° C for 30 minutes, followed by enzyme activation at 
95°C for 15 minutes, then 40 cycles of denaturation at 94°C for 15 seconds and a combined 
annealing/extension step at 60°C for 60 seconds.  For each assay, a standard curve was 
generated using virus standards (101 to 106 TCID50 equivalents per ml) and positive and 
negative control samples were tested with the unknowns. 
Laboratory B.  Oral fluids were shipped overnight on ice to laboratory B.  Samples were not 
frozen when received, but were kept cold and processed the same day as arrival.  qRT-PCR 
was performed as previously described.35  This assay has minor differences in comparison to 
Laboratory A.  Specifically, an MGB 5’ nuclease probe and primers were designed from the 
3’UTR PRRSV genomic region by alignment of GenBankg isolates and based on conserved 
areas of the 3’UTR primer and probe region.  A PCR reaction was considered positive if the 
cycle threshold (Ct) level was obtained at ≤39 cycles.  A standard curve used for qPCR, 
consisted of known amounts of serially diluted in vitro transcript RNA product (1 × 10-1 
through 1 × 108 copies per μl).  Copy per ml concentrations of the unknown samples were 
determined by linear extrapolation of the Ct values plotted against the known concentration 
of the 3’UTR transcript product. 
PRRSV indirect fluorescent antibody 
 Oral fluid samples were assayed for the presence of specific anti-PRRSV IgG and 
IgA antibodies by IFA using fixed MARC-145 cells infected with PRRSV as previously 
described.39 with a few modifications.  Known positive and negative controls were diluted 
1:20 in 0.01M PBS (pH 7.2) with 0.05% Tween® 20 (PBST) while oral fluid samples were 
tested after being diluted 1:2 in PBST.  For detection of anti-PRRSV antibodies, FITC-
conjugated anti-porcine IgGh and FITC-conjugated anti-porcine IgA.h were used as the 
secondary antibody for detection of anti-PRRSV IgG and IgA respectively. 
PRRSV ELISA 
Both oral fluid and serum samples were tested for the presence of antibodies against PRRSV 
using the HerdChek® PRRS Antibody 2XR Test Kit.i Serum samples were diluted 1:50 and 
assayed according to the manufacturer’s instruction.  Oral fluids were assayed according to 
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the manufacturer’s instructions, with the exception that samples were centrifuged at 1000 x g 
for 10 min and diluted 1:2 in dilution buffer provided by the manufacturer prior to being 
assayed.  All ELISA results were expressed as sample/positive (S/P) ratios. 
Statistical methods 
All statistical analyses were performed using JMP 6.0.0.j Serum and oral fluids results for 
ELISA and real-time qRT-PCR were analyzed using multivariate analysis of variance 
(MANOVA) with time as the repeated measure and age as a model effect.  When statistically 
significant (p < 0.05) age-by-time interactions were observed, Tukey’s Honestly 
Significantly Different (HSD) test was used to determine when in time (DPI) the response by 
age differed. 
Linear regression was used to evaluate the relationship between oral fluid samples and serum 
samples with respect to the quantity of viral RNA and, in a separate analysis, ELISA S/P 
values.  Consolidation of data was necessary to conduct linear regression, despite its 
recognized effect on type 2 error rate.  That is, oral fluid samples were collected from pens 
(not individual pigs) at 2- to 4-day intervals, whereas serum samples were collected from 
individual pigs twice a  week through day 14, then weekly.  Thus, the linear regression 
analyses (real-time qRT-PCR, ELISA) were based on a weekly average of oral fluid results 
for each pen and weekly average of serum results for individual pigs within the same pen. 
 Results  
PRRSV real-time qRT-PCR 
Oral fluid samples were assayed by real-time qRT-PCR at two laboratories (A and B).  All 
oral fluid samples collected from negative control pens were negative in both laboratories (n 
= 55).  Overall, 88% of the qualitative results from laboratories A and B were in agreement 
(i.e., 37 positive samples and 147 negative samples of the 209 samples assayed).  Categorical 
results from the two laboratories are given by week postinoculation in Table 1.  Real-time 
qRT-PCR estimates of virus concentration were based on extrapolation to TCID50 standards 
(laboratory A) or transcript RNA product standards (laboratory B).  Linear regression 
analysis showed a positive correlation (r2 = 0.60) between the quantitative estimates from the 
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two laboratories.  Age at the time of inoculation had no effect on the quantity of virus present 
in oral fluid samples (MANOVA: laboratory A, p = 0.21; laboratory B, p = 0.42; Figs. 1, 2; 
Tables 2, 3). 
Given that real-time qRT-PCR results from the two laboratories were comparable, buccal 
swabs and serum samples (reported below) were only assayed at laboratory A.  Buccal swab 
samples were collected from individual pigs twice weekly through 21 DPI.  All samples 
collected prior to inoculation (n = 48) were real-time qRT-PCR negative.  Of 216 buccal 
swabs collected from PRRSV-inoculated pigs on 3, 7, 10, 14, 17, and 21 DPI, 29 were 
positive by real-time qRT-PCR.  One of 72 buccal swab samples collected from negative 
control pigs during the observation period tested positive.  All other specimens (serum, oral 
fluid, buccal swab) collected from negative control pigs tested negative by qRT-PCR and 
ELISA.  This supports the interpretation of this one result as a false positive.  Pig-matched 
serum and buccal swab samples were collected from PRRSV-inoculated pigs on 7, 14, and 
21 DPI.  Of 108 paired samples, 12 were real-time qRT-PCR–positive for both specimens; 92 
were serum-positive and buccal swab–negative; and 4 were negative for both samples. 
Serum samples were collected from all pigs twice weekly through 14 DPI, then weekly 
through 63 DPI.  Analysis (MANOVA) of the real-time qRT-PCR data detected a difference 
(p = 0.0001) in the level of viremia by the age of the pig at the time of inoculation.  Overall, 
the youngest pigs had the highest level of viremia followed by the next youngest group (Fig. 
3, Table 4).  Statistically significant differences in the level of PRRSV viremia by age group 
were identified (Tukey HSD) at 7, 10, and 42 DPI (Table 4). 
Comparison showed that the levels of virus in serum and oral fluid samples followed a 
similar pattern, with oral fluid consistently containing a lower concentration of virus (Fig. 4).  
Both serum and oral fluid samples were real-time qRT-PCR positive from 3 DPI to 4 to 5 
weeks postinoculation, with sporadic positives thereafter.  Linear regression analysis 
estimated the correlation (r2) between virus concentration in serum and oral fluids at 0.56 
(Fig. 5). 
The diagnostic sensitivity of real-time qRT-PCR for serum and oral fluid samples 
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corresponded to the percentage of inoculated animals (or pens) that tested positive (Table 1).  
For oral fluid samples, the mean diagnostic sensitivity for the first 4 weeks postinoculation 
was 88% for laboratory A and 81% for laboratory B.  By comparison, the mean diagnostic 
sensitivity of laboratory A on individual pig serum samples for the same 4-week period was 
89%.  Neither laboratory reported positive real-time qRT-PCR results for serum or oral fluid 
samples from negative controls (i.e., diagnostic specificity was 100%). 
PRRSV ELISA 
Statistical analysis of the serum antibody response found a significant difference in ELISA 
S/P values by pig age at the time of inoculation (MANOVA: p = 0.0001).  The youngest pigs 
had the highest S/P response, followed by the next youngest group (Fig. 6, Table 5).  
Statistically significant differences in S/P values by age group were identified (Tukey HSD) 
from 14 to 63 DPI, with the 4-week-old group consistently showing the highest S/P response. 
In contrast, a comparison of oral fluid ELISA results found no significant difference in least 
square means between PRRSV-inoculated and negative-control pens (MANOVA: p = 0.72).  
Likewise, no significant difference was detected in the ELISA response within the inoculated 
groups by pig age at time of inoculation (MANOVA: p = 0.15). 
PRRSV indirect fluorescent antibody 
Anti-PRRSV IgG was detected by IFA in 20 of 154 oral fluid samples from inoculated pens, 
with positives sporadically distributed across the postinoculation observation period.  No 
anti-PRRSV IgA was detected in oral fluid samples with the protocol described.  Samples 
from negative control pens were negative for both IgG and IgA. 
Discussion 
In humans, viral infections in which the agent is present in oral fluids include hepatitis A,22 
hepatitis B,18 hepatitis C,30 hepatitis G,38 herpes simplex virus type 1,7 human herpesvirus 6,5 
human immunodeficiency virus,10 measles virus,17 mumps virus,17 Mycobacterium 
tuberculosis,18  rubella virus,17 severe acute respiratory syndrome-associated coronavirus,34 
transfusion transmitted virus,38 and varicella-zoster virus.9  Some viral infections were also 
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demonstrated to produce detectable levels of specific antibodies in oral fluids: Dengue virus,6 
hepatitis A,28,29 hepatitis B,28,29 hepatitis C,29 human immunodeficiency virus,28 measles 
virus,27 Norwalk virus,25 rubella virus,27 and others.  In human diagnostic medicine, the 
presence of pathogens and/or antibodies have stimulated important developments in 
diagnostic medicine, e.g., in 2004, the FDA approved a rapid assay (20 min) for detection of 
antibodies against HIV-1 in oral fluid, blood, or plasma samples (Anonymous: 2004, FDA 
approves oral fluid rapid HIV test.  Dentistry Today 23:42).  Likewise, IgG-based assays for 
oral fluid have been developed for Epstein-Barr virus, hepatitis A and B viruses, parvovirus 
B19, and rubella virus24 and assays based on the IgM antibodies have been developed to 
detect recent infections by hepatitis A and B viruses, measles virus, mumps virus, parvovirus 
B19, and rubella virus,24 
In animals, the presence of pathogens in oral fluid has generally been described in the context 
of transmission (e.g., rabies virus).2  In swine, examples of viral pathogens present in oral 
fluids include bovine virus diarrhea virus,33 foot-and-mouth disease virus,1,4 porcine 
circovirus type 2,32 pseudorabies (Aujeszky’s disease) virus,3 and vesicular stomatitis virus.21 
Pathogen-specific antibodies in oral fluids have also been described in animals, although the 
research is extremely limited.  In swine, the appearance of specific antibodies in oral fluids 
was shown following inoculation with Actinobacillus pleuropneumoniae,19,20 cholera toxin B 
subunit,15 and group E Streptococcus spp.16 
The use of oral fluids in veterinary diagnostic medicine has been minimal; for the most part 
limited to the diagnosis of feline immunodeficiency virus.30 Recently, oral fluid samples 
were reported as a method for the detection of E. coli O157:H7 in feedlot cattle (Renter DG, 
Visser A, McFall M et al: 2004, Rapid pen-level surveillance of E. coli O157:H7 in finished 
feedlot cattle.  Animal Health Forum 9(1):3).   
The research reported here represents a further investigation of the application of oral fluids 
to veterinary diagnostic medicine.  In this experiment, the collection of oral fluid samples 
from pens of pigs was determined to be easy and efficient.  Normal pig behavior was 
conducive to sample collection, that is, pigs naturally investigate and chew on new objects 
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within the pen, i.e., rope.  PRRSV was detected by real-time qRT-PCR in oral fluid samples 
for approximately four weeks.  The fact that two laboratories independently arrived at similar 
results (88% agreement) suggests that oral fluid samples could be used to monitor PRRSV 
infection in commercial swine herds using currently available PCR-based assays by testing at 
≤4-week intervals.  Specific anti-PRRSV antibody was detected in oral fluids, but additional 
research will be required to develop diagnostically sensitive assays.  Oral fluid sampling 
must still be validated in the field, but preliminary data suggest that this approach could offer 
a significant improvement in the ease, timeliness, and cost of disease surveillance in 
commercial swine populations. 
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Tables and Figures  
Table 1. Oral fluid, serum, and buccal swab PRRSV real-time qRT-PCR categorical results 
by time post-inoculation 
Week 
Pen-based results* Individual pig results† 
Pen-based oral fluid samples Serum‡ Serum Buccal swabs 
Laboratory A Laboratory B Laboratory A Laboratory A Laboratory A 
1 8 (100%) 8 (100%) 8 (100%) 35 (97%) 7 (20%) 
2 7 (88%) 8 (100%) 8 (100%) 36 (100%) 3 (8%) 
3 6 (75%) 4 (50%) 8 (100%) 32 (89%) 2 (6%) 
4 7 (88%) 6 (75%) 7 (88%) 18 (50%) N/A 
5 2 (25%) 3 (38%) 6 (75%) 10 (28%) N/A 
6 0 3 (38%) 6 (75%) 12 (33%) N/A 
7 1 (13%) 1 (13%) 5 (63%) 7 (19%) N/A 
9 0 0 3 (38%) 5 (14%) N/A 
 
* Number and percent (%) of real-time qRT-PCR positive pens among 8 pens sampled. 
† Number and percent (%) of real-time qRT-PCR positive pigs among 36 pigs sampled. 
‡ Pen was classified positive if one or more individual pig serum samples within pen was 
positive. 
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Table 2. Laboratory A: Oral fluid PRRSV real-time qRT-PCR least square means by pig age 
and week post-inoculation 
Pig age (weeks)† 
Week post-inoculation* 
1 2 3 4 5 6 7 8 9 
4 1.8 1.1 0.0 0.3 0.2 0.0 0.9 0.0 0.0
8 1.8 0.9 0.6 0.2 0.0 0.0 0.0 0.0 0.0
12 1.6 0.7 0.6 0.2 0.0 0.0 0.0 0.0 0.0
 
* PRRSV real-time qRT-PCR results reported as log10 TCID50 equivalents per ml. 
† Pig age at the time of inoculation had no effect on the quantity of virus in oral fluid 
(MANOVA: p = 0.21). 
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Table 3. Laboratory B: Oral fluid PRRSV real-time qRT-PCR least square means by pig age 
and week post-inoculation 
Pig age (weeks)† 
Week post-inoculation* 
1 2 3 4 5 6 7 8 9 
4 5.0 4.3 0.0 2.5 0.0 1.2 1.9 0.0 0.0
8 3.6 3.2 1.7 1.5 0.8 1.0 0.0 0.6 0.0
12 3.8 3.3 1.5 1.7 1.4 0.6 0.0 1.5 0.0
 
* PRRSV real-time qRT-PCR results reported as log10 RNA copies per ml. 
† Pig age at the time of inoculation had no effect on the quantity of virus in oral fluid 
(MANOVA: p = 0.42). 
 
43 
 
             Table 4. Serum PRRSV real-time qRT-PCR least square means by age and day post-inoculation 
Pig age (weeks) 
Day post-inoculation* 
0 3 7 10 14 21 28 35 42 48 56 63 
4 0.0 4.0 4.1† 4.3† 2.5 2.2 1.0 0.5 0.8† 0.3 0.2 0.2 
8 0.0 3.4 3.2†‡ 1.8‡ 2.8 1.4 0.6 0.2 0.0‡ 0.1 0.0 0.0 
12 0.0 3.0 2.1‡ 1.7‡ 2.6 1.0 0.3 0.1 0.3†‡ 0.1 0.1 0.0 
 
  * PRRSV real-time qRT-PCR results reported as log10 TCID50 equivalents per ml. 
  †,‡ Within columns, means with different superscripts were significantly different by Tukey HSD.  
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       Table 5. Serum PRRSV ELISA sample/positive least square means by pig age and day post-inoculation 
Pig age (weeks) 
Day post-inoculation 
0 3 7 10 14 21 28 35 42 48 56 63 
4 0.01 0.04 0.23 0.90 1.84* 2.10* 2.41* 2.26* 2.16* 2.26* 2.27* 2.18* 
8 0.02 0.04 0.15 0.87 1.02† 1.33† 1.61† 1.61† 1.58*† 1.51*† 1.59† 1.51† 
12 0.06 0.06 0.23 1.02 1.06† 1.28† 1.27† 1.27† 1.05† 1.46† 1.36† 1.25† 
 
  *,† Within columns, means with different superscripts were significantly different by Tukey HSD. 
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Figure 1. Laboratory A: Oral fluid PRRSV qRT-PCR least square means by pig age and 
week post-inoculation.  
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Figure 2. Laboratory B: Oral fluid PRRSV real-time qRT-PCR least square means by pig age 
and week post-inoculation  
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Figure 3. Serum PRRSV real-time qRT-PCR least square means by pig age and day post-
inoculation.  
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Figure 4. Serum and oral fluid PRRSV qRT-PCR results by week post-inoculation. 
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Figure 5. Correlation between serum and oral fluid PRRSV qRT-PCR results: (r2 = 0.56)
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Figure 6. Serum PRRSV ELISA least square means by pig age and day post-inoculation 
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CHAPTER 3. SURVEILLANCE OF COMMERCIAL GROWING PIGS FOR 
PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) 
AND PORCINE CIRCOVIRUS TYPE 2 (PCV2) INFECTIONS USING ORAL FLUID 
SAMPLES  
 
A paper published in the Journal of Swine Health and Production 2008 16(2):86-91. 
J Prickett, W Kim, R Simer, K Yoon, J Zimmerman 
 
Summary 
Objectives: To validate the use of oral fluids to detect infections with porcine respiratory and 
reproductive syndrome virus (PRRSV) and porcine circovirus type 2 (PCV2) in three 
commercial swine herds. 
Materials and methods: Oral-fluid and serum samples were collected from one barn on 
each of three PRRSV-infected finishing sites.  Six pens per barn (20 to 30 pigs per pen) were 
sampled repeatedly, beginning when the pigs entered the facilities (3 weeks of age), and then 
at 5, 8, 12, and 16 weeks of age.  Serum samples were tested using a commercial PRRSV 
ELISA.  Both serum and oral-fluid samples were tested for PRRSV by quantitative reverse-
transcriptase polymerase chain reaction (PCR), and oral fluids were tested for PCV2 by qRT-
PCR. 
Results: Site One pigs seroconverted to PRRSV at 12 weeks of age, and Site Two and Three 
pigs at 5 to 8 weeks of age.  All individual serum samples tested PCR-negative for PRRSV in 
pigs 3 to 5 weeks old, while > 1 sample tested positive in pigs 8, 12, and 16 weeks old, with 
77% agreement between oral-fluid and serum pen-level results.  At all sites, > 1 oral-fluid 
sample tested PCR-positive for PCV2 beginning when pigs were 8 weeks old. 
Implications: Oral-fluid samples may be used to monitor PRRSV and PCV2 infections in 
commercial production systems.  PRRSV virus is detectable in oral fluids for 3 to 8 weeks, 
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and PCV2 may be detectable for > 8 weeks.  Sampling at 2- to 4-week intervals is 
recommended for surveillance of PRRSV and PCV2.  
Introduction 
In both humans and animals, antibodies and pathogens may be detected in oral fluids 
collected from infected individuals.  The presence of antibody in oral fluid was demonstrated 
as early as 1909.1  Antibody (IgM, IgA, and IgG) is produced locally in salivary glands and 
lymphoid tissue, but the primary source of antibody in oral fluid is oral mucosal transudate.2  
Pathogens in oral fluids may originate in tissues associated with the buccal cavity (eg, 
classical swine fever virus replicates in the tonsil of the soft palate)3 or reach the buccal 
cavity from the circulatory system via oral mucosal transudate (eg, hepatitis B).4  Examples 
in which both the agent and antibody are present in oral fluids include foot-and-mouth 
disease virus in cattle,5,6 Brucella melitensis in humans,7 and feline immunodeficiency virus 
in cats.8,9 
The body of literature on the use of oral fluids in human diagnostics is extensive,10-12 but 
Archibald et al13 may have been the first to suggest their use as a primary diagnostic 
specimen.  Thereafter, diagnostic assays using oral fluid became available for a variety of 
infections and infectious agents, eg, human immunodeficiency viruses,14 measles,15 mumps,16 
rubella,17 hepatitis A, B, and C,18 and others. 
In veterinary medicine, oral fluids have been used for detection of Escherichia coli 
O157:H719,20 and Salmonella in feedlot cattle,19 and feline leukemia virus in cats.21 In swine, 
specific antibodies were detected in oral fluid from pigs infected with group E 
streptococcus,22 Actinobacillus pleuropneumoniae,23 and cholera toxin B subunit.24 
Both porcine reproductive and respiratory syndrome virus (PRRSV) and porcine circovirus 
type 2 (PCV2) have been detected in buccal samples.25,26  Recently, under experimental 
conditions, oral-fluid samples from pigs inoculated with PRRSV were shown to contain 
diagnostic levels of virus.27  Here, we report a pilot project validating the use of oral fluids 
for detection of PRRSV and PCV2 infections in three commercial swine herds. 
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Materials and Methods 
Experimental design 
Oral-fluid and serum samples were collected on three PRRSV-infected finishing sites 
stocked with pigs from endemically-infected sow farms.  Pigs on Site One were sourced from 
one sow farm, and pigs on Sites Two and Three from a second sow farm.  On each site, six 
pens in one barn (20 to 30 pigs per pen) were sampled repeatedly over time.  Samples were 
collected when the pigs entered the facilities at 3 weeks of age, and then at 5, 8, 12, and 16 
weeks of age.  At each time point, one oral-fluid sample was collected from each pen, and 
blood samples were collected from a convenience sample of five pigs per pen.  At the end of 
the collection period, all oral-fluid and serum samples were randomized, relabeled, and tested 
for PRRSV by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR).  In 
addition, serum samples were tested for anti-PRRSV antibody using a commercial ELISA, 
and oral fluids were tested for PCV2 by qRT-PCR. 
Collection of biological samples 
Oral fluids were collected by hanging a length of cotton rope within the pen for 20 to 30 
minutes.  At each sampling, the rope was positioned at shoulder height for the pigs in the 
pen, ie, the length of the rope was adjusted as the pigs grew.  Pigs are naturally attracted to 
the rope and deposit oral fluids during the process of interacting with it.28 After the exposure 
period, oral fluids were extracted from the rope by wringing the wet end or portion of the 
rope into a 1-gallon resealable plastic bag and clipping a bottom corner of the bag to drain 
the fluid into a 50-mL centrifuge tube.  Samples were stored frozen until assayed. 
Blood samples were collected using a single-use blood collection system (Vacutainer; Becton 
Dickinson, Franklin Lakes, New Jersey).  Blood was centrifuged at 1000g for 10 minutes, 
and serum was harvested and stored at -20°C. 
PRRSV qRT-PCR 
Oral-fluid and serum samples were assayed for PRRSV by qRT-PCR as previously 
described28 with minor exceptions.  Briefly, viral RNA for qRT-PCR amplification was 
extracted from 0.14 mL of sample using an Ambion viral RNA kit (Ambion, Valencia, 
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California) according to the protocols recommended by the manufacturer.  Real-time RT-
PCR quantification was performed using an ABI Prism 7900 HT sequence detection system 
(Applied Biosystems, Foster City, California).  Primers specific for PRRSV open reading 
frame (ORF) 7 were synthesized by Integrated DNA Technologies, Inc (Coralville, Iowa), 
and minor groove binder probes were synthesized by Applied Biosystems.  The thermal 
profile for amplification of PRRSV viral RNA was a reverse transcription at 50°C for 30 
minutes, followed by enzyme activation at 95°C for 15 minutes, then 40 cycles of 
denaturation at 94°C for 15 seconds and a combined annealing-extension step at 60°C for 60 
seconds, with fluorescence data capture at the combined annealing-extension stage.  For each 
assay, a standard curve was generated using standards (101 to 106 median tissue culture 
infections dose [TCID50] equivalents per mL), and positive and negative control samples 
were tested with the unknowns.  The unit of expression for PRRSV qRT-PCR results was 
TCID50 equivalents per mL, which represented the quantity of total viral RNA in samples 
relative to standards in which the amount of infectious PRRSV was quantified using 
microtitration infectivity assays.  A positive sample was defined as a sample that produced a 
TCID50 estimate in the qRT-PCR assay. 
PCV2 qRT-PCR 
The presence of PCV2 in oral fluids was assessed by qRT-PCR using a previously described 
protocol;29 serum samples were not available for testing.  Briefly, viral DNA was extracted 
from 50 µL of each oral fluid sample using MagMax total viral nucleic acid isolation kit 
(Ambion, Valencia, California) according to the manufacturer’s instruction.  Real-time PCR 
was performed with TaqMan Fast Universal PCR Master Mix (Applied Biosystems) in 25-µL 
reaction volumes using 5 µL of extracted template.  The PCR primers (Integrated DNA 
Technologies, Inc) and probe (Applied Biosystems) with 5’ reporter 6-carboxyfluorescein 
(FAM) and a 3’ TAMRA quencher were designed to detect complementary sequences in 
ORF1 of PCV2.  Primers were added at a final concentration of 20 µM each; the probe was 
at a final concentration of 25 µM.  The PCR amplification was performed on the ABI 
7500HT Sequence Detection System (Applied Biosystems).  Cycling conditions were as 
follows: an activation step at 95°C for 20 seconds and then 35 cycles of 3 seconds at 94°C 
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and 30 seconds at 60°C.  A set of PCV2 preparations with known virus titer (fluorescent 
focus forming unit, FFU) was used to generate a standard curve.  Samples with a threshold 
cycle of < 35 cycles were considered positive. 
PRRSV ELISA 
Serum samples were tested for antibodies against PRRSV using the HerdChek PRRS 
Antibody 2XR Test Kit (IDEXX Laboratories, Inc, Westbrook, Maine).  Serum samples were 
assayed according to the manufacturer’s instruction.  As recommended by the manufacturer, 
a positive serum sample was defined as having a sample-to-positive ratio (S:P) value > 0.4. 
Results 
PRRSV ELISA 
Serum ELISA S:P results are presented as means over time (Figure 1).  At all three sites, S:P 
ratios declined between placement (3 weeks of age) and 2 weeks post placement.  In pigs at 
Site One, S:P ratios increased when pigs were 8 to 12 weeks of age, while at Sites Two and 
Three, S:P ratios increased when pigs were 5 to 8 weeks of age.  In contrast, pigs at Site One 
seroconverted between 8 and 12 weeks of age.  That is, all Site One pigs (n = 30) were 
ELISA-negative at 8 weeks of age and ELISA-positive at 12 weeks of age. 
PRRSV qRT-PCR 
All individual pig serum samples collected when the pigs were 3 and 5 weeks of age tested 
PCR-negative.  At all three sites, one or more serum samples (n = 30 per site at each 
sampling) tested PCR-positive in pigs 8, 12, and 16 weeks of age.  At the pen level, 77% of 
PRRSV qRT-PCR oral-fluid and serum results were in agreement (Figure 1).  PRRS virus 
was first detected at Sites Two and Three in oral-fluid samples collected at 8 weeks of age, 
consistent with the serum qRT-PCR results at each site.  However, in all 30 pigs 8 weeks of 
age at Site One, PCR for PRRSV in oral-fluid samples and serum ELISA for PRRSV 
antibodies were negative, while serum PCR was positive in 25 of 30 pigs sampled at Site 1 
(Figure 1).  
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PCV2 qRT-PCR 
Results of testing oral-fluid samples for PCV2 by qRT-PCR are summarized in Table 1.  
Two or more oral-fluid samples from Site One tested positive at all sampling points, 
including all six pens at the last sampling point (16 weeks of age).  At Site Two, all pens 
tested negative at the first sampling, and at Site Three, all pens tested negative at 3, 5, and 8 
weeks of age. 
Discussion 
Surveillance, ie, on-going efforts to detect a pathogenic agent or disease, is fundamental to 
the control, elimination, or eradication of an infectious agent.  Current surveillance methods 
for monitoring PRRSV in the production setting require collection of serum samples from 
individual animals.  The number of samples required, labor, and time associated with serum-
based testing are often cost-prohibitive.  The most frequent consequence is that surveillance 
is ineffectively executed or abandoned altogether. 
Previous data collected under experimental conditions suggested that PRRSV is detectable in 
oral fluid samples for approximately 4 weeks after exposure.28 The objective of this study 
was to conduct a preliminary assessment of the feasibility of detecting PRRSV in oral fluid 
samples collected in an endemically-infected commercial population.  At pen level, 77% of 
the PRRSV qRT-PCR oral fluid and serum results were in agreement.  Pen-based oral fluid 
sampling offers a simple, nontechnical technique for monitoring PRRSV circulation in a 
population.  Further research under experimental conditions and field settings with matched 
sera and oral fluid samples is needed to establish sample size and refine sampling protocols.  
However, the data reported here and the work previously published28 suggest that a sampling 
interval of 2 to 4 weeks would be sufficient for timely and effective PRRSV and PCV2 
surveillance. 
The original experimental design of this study did not include testing for PCV2.  Due to the 
current interest in PCV2, oral fluid samples were tested for PCV2 by qRT-PCR (serum 
samples were no longer available).  Reflecting the ubiquitous distribution of the virus, PCV2 
was detected in oral fluids from each of the three sites and, at Site One, two or more PCR-
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positive oral-fluid samples were recovered at every sampling point.  These data suggested 
that oral-fluid sampling could be used to collect PCV2 for genetic characterization and to 
monitor circulation of PCV2 in commercial populations. 
Implications 
 Under the conditions of this study, testing of oral fluids by PCR may be used to detect 
PRRSV and PCV2 infections in commercial production systems. 
 PRRS virus is detectable in oral fluids for 3 to 8 weeks, and PCV2 may be detectable 
for longer than 8 weeks. 
 Sampling at 2- to 4-week intervals is recommended for surveillance of PRRSV and 
PCV2. 
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Tables and Figures 
Table 1. Categorical individual pig serum results:  PRRSV qRT-PCR and ELISA positives 
by site and pen  
  PRRSV qRT-PCR (ELISA) positives among 5 pigs tested per pen
Site Pig age (weeks) Pen
  1 Pen  2 Pen  3 Pen 4 Pen 5 Pen 6 
        
1 
3 0 (0) 0 (2) 0 (1) 0 (2) 0 (0) 0 (0) 
5 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
8 4 (0) 4 (0) 5 (0) 3 (0) 4 (0) 5 (0) 
12 1 (5)  1 (5)  1 (5)  0 (5)  0 (5)  2 (5)  
16 0 (5) 0 (5) 1 (5) 0 (5) 0 (5) 1 (5) 
        
2 
3 0 (2) 0 (3)  0 (3) 0 (1) 0 (3) 0 (2) 
5 0 (0) 0 (2) 0 (0) 0 (0) 0 (0) 0 (2) 
8 5 (5)  5 (5)  5 (5)  5 (4)  5 (3)  4 (4)  
12 2 (5)  3 (5) 3 (5) 4 (5) 3 (5) 1 (5)  
16 1 (5)  2 (5) 0 (5) 0 (4) 0 (5) 0 (5) 
        
3 
3 0 (1) 0 (3) 0 (2) 0 (0) 0 (0) 0 (2) 
5 0 (0) 0 (2) 0 (1) 0 (1) 0 (0) 0 (1) 
8 4 (5)  5 (5) 5 (5)  5 (5)  5 (4)  5 (5) 
12 3 (5)  1 (5)  1 (5)  0 (5)  0 (5) 1 (5) 
16 0 (5) 0 (5) 0 (5) 0 (5) 0 (4) 1 (5) 
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Table 2. Categorical pen-level (n = 6 pens) results for PRRSVa and PCV2 by site 
  Pen results based on individual pig serum samplesb  
Pen results based on oral 
fluid samples c 
Site Pig age (weeks) PRRSV qRT-PCR (ELISA) 
PRRSV 
qRT-PCR 
PCV2 
qRT-PCR 
     
1 
3 0 (2) 0 2 
5 0 (0) 0 3 
8 6 (0) 0 3 
12 4 (6) 6 2 
16 2 (6) 0 6 
     
2 
3 0 (6) 0 0 
5 0 (2) 0 1 
8 6 (6) 6 2 
12 6 (6) 1 5 
16 2 (6) 1 6 
     
3 
3 0 (4) 0 0 
5 0 (4) 0 0 
8 6 (6) 4 0 
12 4 (6) 4 1 
16 1 (6) 0 6 
 
a PRRSV qRT-PCR oral fluid and serum results showed 77% agreement at the pen level 
b Number of positive pens among 6 pens sampled per site.  Pen defined as positive if ≥1 pig 
serum sample tested positive 
c One oral fluid sample collected from each pen (6) per sampling point  
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Figure 1. Cumulative results of testing oral fluids and serum by PRRSV qRT-PCR, testing 
oral fluids by PCV2 PCR, and serum antibodies by PRRSV ELISA in three 
commercial finisher sites 
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CHAPTER 4. STABILITY OF PCR-DETECTABLE PORCINE REPRODUCTIVE 
AND RESPIRATORY SYNDROME VIRUS (PRRSV) AND ANTI-PRRSV 
ANTIBODY IN SWINE ORAL FLUID 
 
A paper submitted to the Journal of Swine Health and Production 
J. Prickett, S Cutler, J Kinyon, N Naberhaus, W Stensland, K Yoon, J Zimmerman 
 
Summary 
Objective:  The objective of this research was to evaluate the stability of porcine 
reproductive and respiratory syndrome virus (PRRSV) and anti-PRRSV antibodies in oral 
fluid as a function of time and temperature.   
Materials and methods:  A 4-liter pool of swine oral fluid was collected from 16-week old 
finisher pigs.  To ensure uniform, quantifiable levels of virus and antibody over time, the 
pool was “spiked” with 4 ml of PRRSV isolate ISU-P containing 1 x 1012 RNA copies per ml 
and 10 ml of concentrated hyper-immune anti-PRRSV antibodies.  The pool was divided into 
3 equal portions: (1) no treatment; (2) chlorhexidine digluconate at 0.01% by volume; (3) 
isothiazolinone at 3 parts per million.  Each treatment was run in triplicate at each of five 
temperatures (-20°C, 4°C, 10°C, 20°C, 30°C).  Samples were removed at specific intervals (0 
hr, 12 hr, 24 hr, 48 hr, 72 hr, 144 hr, 216 hr, and 288 hr), stored at -80ºC, and then assayed 
for: (1) PRRSV RNA; (2) IgM, IgA, and IgG; (3) ELISA-detectable PRRSV-specific 
antibody; (4) culturable bacteria per ml.    
Results:  The results showed that the stability of anti-PRRSV antibody and PCR-detectable 
PRRSV was highly temperature-dependent, with antimicrobial treatment providing no 
improvements in stability at lower temperatures.  In particular, both virus and antibody were 
stable at ≤ 10°C over 12 days of storage.  
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Implications:  Conventional serum storage protocols (freezing or refrigeration at 4°C) will 
preserve PRRSV and anti-PRRSV antibody in oral fluid diagnostic samples. 
Introduction 
Oral fluid specimens have been widely used in human medicine and forensics for the 
diagnosis or detection of a variety infectious agents, hormones, toxins, and drugs.1,2,3 When 
used in the surveillance of infectious disease, oral fluid testing facilitates the efficient 
collection of large numbers of diagnostic samples at low cost.  For example, the New York 
City Department of Health and Mental Hygiene performed 166,058 oral fluid rapid HIV 
antibody tests between March 2005 to May 2008 in 10 walk-in clinics.4  In the United 
Kingdom, oral fluid samples were collected from 11,698 children at home and mailed to the 
laboratory for antibody testing.5 
Oral fluids have not been widely exploited in veterinary diagnostic medicine, but the 
detection of pathogens and/or antibodies in swine oral fluids, i.e., porcine circovirus type 2 
(PCV2),6,7 porcine reproductive and respiratory syndrome virus (PRRSV),7,8,9 influenza virus 
(Prickett et al., March 2009.  Cost effective PRRSV surveillance.  Proc AASV.  Dallas, 
Texas, pp. 467-469.), transmissible gastroenteritis virus (TGEV),10 and Actinobacillus 
pleuropneumoniae11,12 suggests this approach could be used in the surveillance of these 
pathogens in commercial swine herds.  
Oral fluids inherently contain endogenous antiviral and antibacterial factors that could 
theoretically affect the stability of PCR targets.13-17 Furthermore, normal oral bacterial flora 
and environmental bacterial contaminants present in livestock facilities could produce 
bacterial proteases capable of enzymatic cleavage of immunoglobulins.18 Therefore, the 
objective of this research was to evaluate the stability of PCR-detectable PRRSV and anti-
PRRSV antibody in oral fluids and develop handling and storage guidelines for porcine oral 
fluid specimens. 
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Materials and Methods 
Experimental design 
The effects of antimicrobial treatment, storage temperature, and storage time were evaluated 
in respect to: (1) total detectable PRRSV RNA; (2) total porcine IgM, IgA, and IgG; (3) 
ELISA-detectable PRRSV-specific antibody; (4) total bacteria; and (5) pH.  To conduct the 
experiment, 4 liters of swine oral fluid was collected from 12-week-old commercial finisher 
pigs and “spiked” with a type 2 PRRSV isolate and anti-PRRSV antibodies.  To test the 
effect of antimicrobials on diagnostic target stability, the pool was divided into 3 treatments: 
(1) untreated control (no trt); (2) chlorhexidine digluconate (chlx; 0.01% by volume); and (3) 
isothiazolinone (kat; 3 ppm).  To ensure the uniform distribution of virus, antibody, and 
antimicrobials, the solution was stirred constantly using a magnetic mixer throughout the 
process of preparation and transfer.  To test the effect of treatment by storage temperature 
and time, 2.5 ml volumes of each antimicrobial treatment were aliquoted into 5ml tubes and 
held at each of five temperatures (-20°C, 4°C, 10°C, 20°C, 30°C).  Three tubes (replicates) 
from each antimicrobial treatment and temperature combination were removed at specific 
times (0 hr, 12 hr, 24 hr, 48 hr, 72 hr, 144 hr, 216 hr, 288 hr) and held at -80°C until tested.  
Thereafter, samples were randomized, tested, and the results evaluated for treatment, time, 
and temperature effects on concentrations of antibody, bacteria, and PCR-detectable PRRSV. 
Porcine oral fluid 
A pool of swine oral fluid (4 liters) was obtained from a population of 16-week-old 
commercial finisher pigs housed in a 2,400 head facility located in Iowa.  Pigs were allowed 
to chew on cotton ropes, after which oral fluids were mechanically extracted, as previously 
described.8  The herd had been vaccinated for PVC2 and Mycoplasma hyopneumoniae at 
approximately 6 weeks of age and had seroconverted to PRRSV between 10 and 14 weeks of 
age. 
PRRSV 
Four ml of PRRSV isolate ISU-P (1 x 1012 RNA copies per ml) were added to the pool of 
oral fluid.  The isolate was initially recovered from lung tissues collected from young pigs in 
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a herd experiencing an acute outbreak of PRRSV in Illinois.  As described elsewhere,19 the 
virus was initially isolated on porcine alveolar macrophage (PAM) cultures and then cloned 
by three rounds of limiting dilutions on PAMs, and twice by plaquing on MA-104 cells.  The 
working stock of virus used in the present study represented the fourth passage in MA-104 
cells. 
Anti-PRRSV antibodies 
Anti-PRRSV antibody (kindly provided by Dr. Fernando Osorio) was produced by hyper-
immunizing 13 pigs against several PRRSV isolates, as previously described.20 In brief, 
hyper-immunization produced neutralizing antibody titers of 1:32-1:128 in all 13 pigs.  
Thereafter, animals were euthanized and exsanguinated.  Serum antibodies from each animal 
were precipitated and concentrated by NH2SO4 treatment.  The concentrated antibodies used 
in this study represented a pool from all 13 animals.  Prior to adding to the pool of oral fluids, 
the concentrated antibodies were reconstituted in 10 ml of phosphate buffered saline. 
Anti-microbial agents 
The effect of antimicrobial preservatives on the stability of PRRSV and anti-PRRSV 
antibody was tested by adding chlorhexidine digluconate or isothiazolinone to oral fluid at 
concentrations of 0.01% and 0.003% (3 ppm), respectively.  Biguanides, i.e., chlorhexidine 
digluconate, act against non-sporulating bacteria and yeasts by disrupting cell membranes.21 
Isothiazolones inhibit metabolic pathways by reacting with thiol-containing enzymes, thereby 
leading to cell death.22 Pilot standard plate count (SPC) assays using a “checkerboard” of 
antimicrobial concentrations were conducted to select bacteriostatic, not virucidal, 
concentrations (data not shown). 
Standard plate count 
The total number of bacteria per ml in each sample was quantified using a SPC method.23 In 
brief, samples were thawed at 23°C for 20 min and then serially diluted in PBS from 1x10-1 
through 1 x 10-7.  To perform the assay, all dilutions, including the undiluted sample, were 
plated in 10 μl volumes on culture plates containing trypticase soy agar with 5% sheep blood.  
Plates were incubated in 5% CO2 at 35°C for 72 hr.  Colonies were counted manually and the 
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total bacteria per ml was estimated and reported in log10 values, with ≥1 x 108 considered the 
upper limit of detection. 
PRRSV real-time RT-PCR 
PRRSV RNA for qRT-PCR amplification was extracted from oral fluid samples with a 
commercially available viral RNA isolation kit(Applied Biosystems, Foster City, CA).  The 
manufacturer’s protocol was modified by increasing the initial volume of the sample from 50 
μl to 175 μl.  This volume of sample was added to 235 μl of lysis/binding solution (provided 
in the kit) to which carrier RNA had been added (provided in the kit) in a 96-well plate.  The 
plate was sealed and placed onto an orbital plate shaker for 3 min at the highest setting, after 
which cell debris was removed by centrifugation of the plate at 1500 x g for 6 min.  
Thereafter, 115 μl of the supernatant was transferred to a 96-well plate containing 65 μl of 
100% isopropanol in each well.  The remainder of the RNA extraction protocol was 
performed according to the manufacturer’s instruction. 
Real-time RT-PCR reactions performed using a commercially available PRRSV PCR kit 
(Applied Biosystems, Foster City, CA ) and analyzed according to manufacturer’s 
recommendations.  Positive and negative plate control samples were run with the oral fluid 
samples.  A standard curve was generated using the genomic copy standards provided in the 
kit (1 x 105 to 1 x 1010 genomic copies per ml) and the results were expressed as PRRSV 
genomic equivalents per ml (log10). 
PRRSV ELISA 
All oral fluid samples were tested for antibodies against PRRSV using a commercially 
available PRRSV antibody ELISA (IDEXX Laboratories, Inc., Westport, ME.) and a 
modified protocol: (1) oral fluid samples were diluted 1:3 using the kit diluent, (2) the diluted 
oral fluid samples were incubated on the ELISA plates overnight at 4°C, and (3) plates were 
brought to room temperature in the morning (30 min) and the remainder of the assay was 
completed according to the manufactures protocol.  The results were reported as sample-to-
positive (S/P) ratios and the response to temperature, time, and treatment was analyzed as 
continuous data, i.e., no “cut-off” value was established or used in this study. 
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Immunoglobulin isotype quantification 
All samples were assayed for IgA, IgG, and IgM antibodies using isotype-specific total swine 
antibody quantification assays following the procedures provided by the manufacturer 
(Bethyl Laboratories, Inc., Montgomery, TX).  Prior to testing, the samples were heat-
inactivated at 56°C for 10 min.  Preliminary assays were performed to determine dilution 
ranges required to quantify each immunoglobulin class.  Each sample was serially diluted 
(1:20–1:160 for IgM and 1:50–1:400 for IgG and IgA) in diluent provided by manufacturer 
in a 96-well round bottom plates.  Samples were then transferred to the kit ELISA plates and 
the assay completed.  The optical density (OD) response was used to estimate the 
concentration of immunoglobulin in each sample using the linear portion of the standard 
curve, with appropriate adjustment for sample dilution.  Samples that were nonresponsive at 
the initial dilutions were re-assayed at lower dilutions (1:2–1:20 for IgM and 1:2–1:50 for 
IgG and IgA).  By definition, samples that were nonresponsive at the lowest dilution, i.e., 
1:2, contained ≤5 ng per ml of respective antibody. 
Measurement of pH 
The pH of 1 of the 3 replicates collected at each sampling point was measured using a pH 
meter calibrated using commercially available standards of pH 4, 7, and 10 (Sigma-Aldrich, 
St. Louis, MO).  The pH probe was washed in de-ionized water and blotted dry between each 
measurement.  Calibration of the pH meter was verified at the beginning, middle, and end of 
testing. 
Statistical methods 
All analyses were performed using commercial statistical software (JMP® 7.0.2, SAS 
Institute Inc., Cary, NJ.).  Initially, the results of each assay were examined for the effect of 
temperature and treatment using analysis of variance (ANOVA).  Temperature, antimicrobial 
treatment, and temperature*antimicrobial treatment were denoted as fixed effects in the 
model.  Thereafter, planned orthogonal comparisons by Student’s t-test were used to identify 
significant differences among treatments and temperatures using the least squares means of 
the assay results.  For clarity in graphical presentation, data were combined if no statistical 
difference was detected between storage temperatures. 
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Results 
Standard plate count 
Statistical analysis of main effects (marginal means) showed that both temperature and 
antimicrobial treatment had significant effects on the level of bacteria detected by the SPC 
(Table 1, Fig. 1).  Two temperature groups were identified on the basis of SPC results (Fig. 
3).  In order of increasing mean SPC (Fig. 1), the two groups were: (–20°C = 4°C = 10°C) < 
(20°C = 30°C).  Significant differences were detected among treatments, but chlorhexidine 
treatment produced the lowest SPC results at all temperatures. 
PRRSV real-time RT-PCR 
Statistical analysis of main effects (marginal means) showed that temperature, but not 
antimicrobial treatment, had a significant effect on the stability of PCR-detectable PRRSV 
(Table 2).  Three temperature groups were identified on the basis of PRRSV qRT-PCR 
results (Fig. 2).  In order of declining concentrations of virus, the three groups were: (–20°C 
= 4°C = 10°C) > (20°C) > (30°C).  In particular, the concentration of PRRSV in 
chlorhexidine-treated samples was significantly lower than other treatments at –20°C, 4°C, 
and 10°C and significantly higher than other treatments at 30°C. 
PRRSV ELISA 
Statistical analysis of main effects (marginal means) showed that both temperature and 
antimicrobial treatment had significant effects on the stability of ELISA-detectable anti-
PRRSV antibody (Table 3).  Three temperature groups were identified on the basis of 
PRRSV ELISA results (Fig. 3).  In order of declining mean ELISA S/P ratios, the groups 
were: (–20°C = 4°C = 10°C) > (20°C) > (30°C).  In particular, the mean ELISA S/P ratios in 
chlorhexidine-treated samples were significantly higher than other treatments at 30°C. 
Total swine immunoglobulin isotype quantification ELISAs 
Concentration (log10 ng per ml) of total swine IgG, IgA, and IgM antibody in oral fluid 
samples by time, temperature, and treatment are shown in Figures 4, 5, 6.  For IgG and IgA, 
two temperature groups were identified on the basis of statistically significant differences: (-
20°C = 4°C = 10°C = 20°C) > (30°C).  At 30°C, higher levels of IgG and IgA were measured 
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in chlorhexidine- and isothiazolinone-treated samples over time relative to no treatment.  For 
IgM, no significant difference was found among results by temperature or treatment. 
Measurement of pH 
Statistical analysis of main effects (marginal means) showed that both temperature and 
antimicrobial treatment had significant effects on pH levels (Table 4).  Three temperature 
groups were identified on the basis of pH levels: (–20°C = 4°C = 10°C) > (20°C) > (30°C). 
Discussion 
Oral fluids have been shown to be a convenient diagnostic specimen for the detection of 
infectious agents and antibodies.6-8,10,11 The present study addressed the question of PRRSV 
and anti-PRRSV antibody stability in oral fluid as a function of time and temperature, both 
with and without anti-microbial preservatives.  Stability was evaluated over a 12-day 
observation period to test extreme sample handling and storage on diagnostic results.  
Standard plate count data showed that bacterial proliferation was reduced by chlorhexidine at 
all temperatures tested.  The concentration of isothiazolinone tested in this study did not 
produce a measurable effect on bacterial proliferation.  Importantly, untreated samples 
contained concentrations of PCR-detectable PRRSV RNA and ELISA-detectable anti-
PRRSV antibody at levels equal or greater than preserved samples when held at temperatures 
≤10°C.  Thus, preservatives were not required, if the cold-chain were maintained. 
There are few publications with which to compare these data.   A search of the literature 
yielded no prior reports on the stability of PCR-detectable viral or bacterial agents by time 
and temperature in oral fluids.  However, our data are in agreement with published data 
reporting that the concentration of antibodies in human oral fluids declined as a function of 
increasing time and higher temperature.22,24,25  
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Implications 
● PRRSV and anti-PRRSV antibodies are relatively resistant to degradation in oral fluids. 
● Use of antimicrobials is not necessary for the preservation of diagnostic targets if 
appropriate handling, storage, and transport protocols are implemented.  
● Appropriate specimen handling protocols, i.e., freezing or refrigeration at 4°C, will 
maintain the integrity of PRRSV and anti-PRRSV antibodies in oral fluid samples collected 
for diagnostic testing. 
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Tables and Figures 
Table 1. Standard Plate Count log10 cells per ml (LS means) 
Temperature Chlorhexidine Isothiazolinone No Treatment Temperature means 
30°C 4.2 E 7.4 BCD 7.4 BCD 6.3 A 
20°C 3.7 E 7.8 ABC 8.1 AB 6.5 A 
10°C 0.7 F 6.7 D 8.1 AB 5.2 B 
4°C 0.8 F 7.0 CD 8.2 A 5.4 B 
-20°C 0.7 F 6.9 D 7.4 ABCD 5.0 B 
Treatment 
means 2.0 C 7.2 B 7.9 A 
 
      
    Values not connected by the same letter are significantly different 
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Table 2. PRRSV qRT-PCR log10 genomic copies per ml (LS means)  
Temperature Chlorhexidine Isothiazolinone No Treatment Temperature means 
30°C 5.6 D 4.1 E 4.3 E 4.7 C 
20°C 6.3 CD 6.8 BC 6.7 BC 6.6 B 
10°C 6.8 BC 7.8 A 7.7 A 7.5 A 
4°C 6.9 BC 7.7 A 7.3 AB 7.3 A 
-20°C 6.6 BC 7.8 A 7.8 A 7.4 A 
Treatment 
means 6.5 A 6.8 A 6.8 A 
 
 
   Values not connected by the same letter are significantly different  
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Table 3. PRRSV ELISA S/P (LS means)  
Temperature Chlorhexidine Isothiazolinone No Treatment Temperature means 
30°C 1.3 BC 0.8 D 0.7 D 0.9 C 
20°C 1.4 AB 1.3 BC 1.1 C 1.3 B 
10°C 1.6 A 1.5 AB 1.6 A 1.6 A 
4°C 1.6 A 1.5 AB 1.7 A 1.6 A 
-20°C 1.6 A 1.6 A 1.6 A 1.6 A 
Treatment 
means 1.5 A 1.3 B 1.4 B 
 
 
    Values not connected by the same letter are significantly different  
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Table 4. pH (LS means)  
Temperature Chlorhexidine Isothiazolinone No Treatment Temperature means 
30°C 8.1 DEF 7.8 G 7.9 FG 7.9 C 
20°C 8.4 BCD 8.0 EFG 8.0 EFG 8.1 B 
10°C 8.6 AB 8.4 BC 8.3 CDE 8.4 A 
4°C 8.6 AB 8.3 BCD 8.3 BCD 8.4 A 
-20°C 8.3 BCD 8.5 ABC 8.7 A 8.5 A 
Treatment 
means 8.4 A 8.2 B 8.2 B 
 
 
     Values not connected by the same letter are significantly different  
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Figure 1. Standard plate count (log10 cells per ml) over time by temperature and storage time
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Figure 2. PRRSV qRT-PCR (log10 genomic copies per ml) over time by temperature and 
storage time  
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Figure 3. PRRSV ELISA (S/P) over time by temperature and storage time  
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Figure 4. Total swine IgG (log10 nanograms per ml) over time and storage temperature
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Figure 5. Total swine IgA (log10 nanograms per ml) over time and storage temperature
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Figure 6. Total swine IgM (log10 nanograms per ml) over time and storage temperature
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CHAPTER 5. PROLONGED DETECTION OF PORCINE CIRCOVIRUS TYPE 2 
(PCV2) AND ANTI-PCV2 ANTIBODY IN ORAL FLUIDS FOLLOWING 
EXPERIMENTAL INOCULATION 
 
A paper to be submitted to Veterinary Research. 
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Abstract 
The onset, level, and duration of quantitative polymerase chain reaction-detectable PCV2 and 
anti-PCV2 antibody in oral fluid was evaluated using samples collected from experimentally-
inoculated pigs for 98 days post inoculation (DPI).  Pigs (n = 24) were obtained at 3 weeks of 
age and randomly allocated to 4 treatment pens of 6 pigs each:  (1) negative control group;  
(2) inoculated with PCV2a (strain ISU 40895) on DPI 0;  (3) inoculated with PCV2a (strain 
ISU-40895) on DPI 0 and re-challenged at DPIs 35 and 70;  (4) inoculated with PCV2a (ISU-
40895), PCV2b (PVG4072), and PCV2a (ISU-4838) on DPIs 0, 35, and 70, respectively.  
Serum was collected from each animal and one oral fluid sample was collected from each 
pen (group) every other day from DPI 2 through DPI 14 and weekly through 98 DPI.  Oral 
fluid samples were assayed for the presence of PCV2 by PCR, anti-PCV2 IgG antibody by 
enzyme linked immunosorbent assay (ELISA), and anti-PCV2 antibody isotypes (IgA, and 
IgM) by ELISA.  Serum was assayed for anti-PCV2 IgG by ELISA.  Anti-PCV2 antibodies 
(IgG, IgM, and IgA) were detected in oral fluid from experimentally inoculated pigs from 14 
to 98 DPI.  PCV2 was detected by PCR in oral fluid samples from all pens of inoculated pigs 
at 2 DPI.  Thereafter, PCV2 was detected in oral fluid throughout DPI 98.  Overall, the data 
indicated that PCV2 infection in swine populations can be efficiently monitored using oral 
fluid specimens. 
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Introduction 
Porcine circovirus Type 2 (PCV2) is a small circular DNA virus belonging to the family 
Circoviridae (Tischer et al.,1982).  There are currently three known strains of PCV2.  PCV2a 
was demonstrated in tissue samples archived in 1962 (Jacobsen, 2009),  PCV2b was first 
reported in North America in 2005 ( Cheng, 2009; Hesse, 2008), and PCV2c was recently 
reported in Denmark from archived serum samples collected from non-clinical pigs in 1980, 
1987 and 1990 (Dupont et al., 2008).  PCV2c isolates are more closely related to PCV2b 
(95%) than PCV2a (91-93.6%) in sequence homology (Dupont et al., 2008).  
PCV2 is present in commercial swine herds worldwide and within infected herds, infection 
approaches 100% of pigs (Opriessnig et al., 2004c).  Transmission of PCV2 occurs as a result 
of direct contact with oronasal secretions, feces, and urine (Bolin et al., 2001; Magar et al., 
2000, Shibata et al., 2003).  The effect of PCV2 on pig health is highly variable, ranging 
from subclinical infection to acute mortality.  Although essentially all herds are infected and 
relatively few herds exhibit clinical signs, some affected herds experience massive losses 
(Opriessnig et al., 2007).  To provide clarity to the broad range of clinical consequences of 
PCV2 infection, the American Association of Swine Veterinarians (AASV) adopted the term 
"porcine circovirus-associated disease" (PCVAD) and provided case definitions and criteria 
for the diagnosis of PCVAD (Anon, 2007).  According to these guidelines, PCVAD includes 
subclinical infection, multisystemic disease with weight loss (formerly known as PMWS), 
high mortality without an alternate etiology, respiratory signs, enteric signs, porcine 
dermatitis and nephropathy syndrome (PDNS), and reproductive disease.   
There is need for reliable and economical methods to monitor PCV2 circulation in swine 
populations.  Oral fluid samples were previously shown to reflect the circulation of 
pathogens in swine populations (Prickett et al., 2008b) and PCV2 has been detected in oral 
fluid collected from gnotobiotic (Allan and Ellis, 2000) and finishing pigs ( Prickett et al., 
2008b).  Therefore, the objectives of this research were to determine the onset, level, and 
duration of PCV2 and anti-PCV2 antibody in oral fluid samples from experimentally 
inoculated pigs.   
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Materials and Methods 
Experimental design 
The onset, level, and duration of PCR-detectable PCV2 and anti-PCV2 antibody in oral fluid 
was evaluated using samples collected from experimentally-inoculated pigs for 98 days post 
inoculation (DPI).  Pigs (n = 24) were obtained at 3 weeks of age from a commercial swine 
herd free of PRRSV and influenza virus, but seropositive for PCV2, and housed thereafter in 
research facilities at Iowa State University in Ames, Iowa.  Prior to PCV2 inoculation, 
animals were monitored for the decay of anti-PCV2 maternal antibody until sample-to-
positive (S/P) values were ≤ 0.2.  At 11 weeks of age, animals were randomly allocated to 
four treatment pens of 6 pigs each (Table 1):  (1) negative control group;  (2) inoculated with 
PCV2a (strain ISU 40895) on DPI 0;  (3) inoculated with PCV2a (strain ISU-40895) on DPI 
0 and re-challenged at DPIs 35 and 70;  (4) inoculated with PCV2a (ISU-40895), PCV2b 
(PVG4072), and PCV2a (ISU-4838) on DPIs 0, 35, and 70, respectively.  All viruses were 
administered as one ml intramuscular (IM) and 2 ml intranasal (IN) inocula.  PCV2a 40895 
and PCV2b PVG4072 were used at a dose of 104.5 50% tissue culture infectious dose 
(TCID50) per ml and PCV2b 4838 was used at a dose of 0.5 x 103.5 TCID50 per ml.  Serum 
was collected from each animal and one oral fluid sample was collected from each pen 
(group) every other day from DPI 2 through DPI 14 and weekly through 98 DPI.  Oral fluid 
samples were assayed for the presence of PCV2 by quantitative PCR, anti-PCV2 IgG 
antibody by enzyme linked immunosorbent assay (ELISA), and anti-PCV2 antibody isotypes 
(IgA, and IgM) by ELISA.  Serum was assayed for anti-PCV2 IgG by ELISA.    
Animals and animal care 
The experimental protocol was approved by the Iowa State University Institutional Animal 
Care and Use Committee (#3-06-6083-S).  Throughout the experiment, animals were housed 
on the floor in pens that were cleaned daily.  Feeder space, square footage per animal, 
ambient temperature, and room air exchanges all met or exceeded guidelines and 
requirements set forth in the Guide for the Care and Use of Agricultural Animals in 
Agricultural Research and Teaching (Federation of Animal Sciences Societies, 1999).  
Animals were fed ad libitum an age-appropriate commercial feed that met or exceeded the 
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nutritional requirements for swine as determined by the National Research Council (National 
Research Council, 1998).  
Porcine circovirus type 2 (PCV2) 
PCV2 strain 40895 (PCV2a) (GenBank accession number AF264042) was recovered from an 
Iowa farm in 1998  and has been well characterized genetically (Fenaux et al., 2000) and in 
the SPF pig model (Fenaux et al., 2003; Fenaux et al., 2004; Opriessnig et al., 2004a,b,c; 
Opriessnig et al., 2003).  PCV2 strain PVG4072 was isolated from lung tissue homogenate 
obtained from a pig presenting clinical PCVAD in a farm experiencing approximately 25% 
mortality in Indiana.  PCV2 isolate 4838 (PCV2a) (GenBank accession number DQ397521) 
was recovered from a subclinically-infected pig on an Iowa farm in 2003 (Fenaux et al., 
2002).  
Collection of serum and oral fluid samples 
Blood samples were collected using a single-use blood collection system (Becton, Dickinson 
and Company, Franklin Lakes, NJ) and centrifuged at 1000 x g for 10 min.  Serum was 
harvested, aliquoted, and stored at –80°C.  Pen-based oral fluid samples were collected by 
suspending a length of 3-strand twisted cotton rope in each pen for 20 min (Prickett et al. 
2008a).  Oral fluid was extracted from each rope, aliquoted, and stored at –80°C.   
PCV2 quantification 
The completed PCR protocol has been described elsewhere (Oprissnig et al., 2004b).  In 
brief, PCV2 nucleic acid extraction from serum and oral fluid samples was performed using 
the QIAamp® DNA Mini Kit (Qiagen, Valencia, CA) according to the manufactures 
protocol. DNA-extracts were used for quantification of PCV2 genomic DNA by real-time 
PCR and expressed as genomic copies per ml. 
PCV2 serum IgG antibody ELISA  
Serum samples were tested in duplicate for anti-PCV2 antibody by ELISA (Nawagitgul et 
al., 2002).  In brief, serum samples were diluted 1:100 in 5% non-fat dry milk in PBS 
(NFDM) diluents and assayed in two wells coated with partially-purified recombinant open 
reading frame two (ORF2) protein produced in baculovirus-infected insect cells.  To measure 
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background reactivity, serum samples were concurrently assayed in two wells coated with 
baculovirus-infected insect cells (SF-9 cells, Invitrogen 11496-015, Carlsbad, CA).  Controls 
consisted of PCV2 antibody-positive serum diluted with PBS to the appropriate range of 
reactivity and antibody-negative serum from a cesarean-derived, colostrum-deprived pig 
determined to be free of PCV2.  Antibody-antigen reactions were detected using horseradish 
peroxidase-labeled anti-swine IgG antibody (KPL 78526) diluted 1:2000 in PBS followed by 
the addition of tetramethylbenzidine (TMB, KPL 52-00-03, Gaithersburg, MD).  The 
response was read at 405 nm and measured as optical density (OD).  The results were 
corrected for non-specific reactivity and reported as sample-to-positive (S/P) values:   
S/P   ൌ ሺ୫ୣୟ୬ ୱୟ୫୮୪ୣ ORFଶ ୵ୣ୪୪ OD ି ୫ୣୟ୬ ୱୟ୫୮୪ୣ ୠୟୡ୳୪୭୴୧୰୳ୱ ୵ୣ୪୪ ODሻሺ ୫ୣୟ୬ ୮୭ୱ୧୲୧୴ୣ ୡ୭୬୲୰୭୪ ORFଶ ୵ୣ୪୪ OD ି ୫ୣୟ୬ ୮୭ୱ୧୲୧୴ୣ ୡ୭୬୲୰୭୪ ୠୟୡ୳୪୭୴୧୰୳ୱ ୵ୣ୪୪ ODሻ 
S/P results ≥ 0.30 were considered positive for anti-PCV2 antibody.  
Oral fluid PCV2 IgM-, IgG-, IgA-specific antibody ELISAs 
Preparation and purification of PCV2 nucleocapsid antigen          An ELISA based on PCV2 
nucleocapsid protein was used to characterize the anti-PCV2 antibody response (IgM, IgA, 
IgG) in oral fluids.  To produce PCV2 nucleocapsid protein, a 549bp sequence of the PCV2 
capsid gene lacking 39 amino acids in the amino terminal and 10 amino acids in the carboxyl 
terminal was amplified with PCV2-specific primers containing BamH1 (New England 
Biolabs, MA) and Zho1 (New England Biolabs, MA) restriction enzyme sites: 5’ CGC GGA 
TCC ATG AAA AAT GGC ATC TTC AAC ACC CGC CT 3’and 5’CCG CTC GAG TTC 
TCT GAA TTG TAC ATA CAT GGT3’.  PCR amplification was carried out in a 50μl 
reaction tube containing 1x PCR buffer, 0.5ng per μl template, 0.25μM of each primer, 
0.2mM of dNTPs, and 0.25μl of taq polymerase (AmpliTaq Gold®, Applied Biosystems, 
5units per μl).  After an initial denaturation at 95°C for 10 min, PCV2 capsid gene was 
amplified by 45 cycles of denaturation at 94°C for 30s, annealing at 55°C for 35s, extension 
at 72°C for 40s, and final extension at 72°C for 7 min.  After PCR amplification, the product 
was tested on 1.2% agarose gel for the correct band size and then purified (PCR purification 
kit, Qiagen®, Valencia, CA) and digested with restriction enzymes BamH1 and Zho1 for 
2hrs at 37°C.  The digested PCR product was then re-purified (PCR purification kit, 
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Qiagen®, Valencia, CA).  A modified pET24b vector (Novagen, Madison, WI) with a 5’ 
myc tag and a terminal 3’ His tag was used to clone the truncated PCV2 capsid gene.  Cap 
PCV2-pET24b was then transformed to XL-10 gold competent cells (Stratagene, La Jolla, 
CA) and spread onto Luria Bertani (LB) agar plates ( Difco, Lawrence, KS) containing 30ug 
per ml kanamycin (Sigma-Aldrich, St. Loius, MO ) and screened by colony PCR using T7 
forward and reverse primers of pET24b plasmid.  Purified plasmids from positive colonies 
were further confirmed by DNA sequencing for the integrity of capsid genes.  Once the 
sequence was confirmed, recombinant plasmid was transformed into BL21 (DE3)-RP cells 
(Stratagene, La Jolla, CA) and spread onto LB plates containing kanamycin at 30µg per ml 
and chloramphenicol (Sigma-Aldrich, St. Loius, MO) at 35µg per ml.  Ten well-grown 
isolated colonies were transferred and grown overnight at 37°C in LB medium with 
antibiotics and then 200 µl of each colony was inoculated into 10ml of 2xYT containing 
kanamycin at 30μg per ml.  These cultures were grown at 37°C to an OD (600 nm) of 0.5 to 
0.6.  Half of the culture was then removed for an un-induced control and the remaining half 
was induced with isopropyl β-D-thiogalactoside (IPTG; Calbiochem, San Diego, CA) at a 
concentration of 1.0mM.  The induced cultures were incubated at 37°C for 4hrs and then 200 
μl from induced and un-induced cultures were analyzed by SDS-PAGE.  After confirming 
the expression in small scale culture, E. coli BL21 RP-containing recombinant plasmid was 
grown in one litre culture and the expressed protein was purified by Ni-NTA agarose bead 
affinity chromatography (Qiagen®, Valencia, CA).  Briefly the culture was centrifuged at 
17,600 x g for 10 min and supernatant was discarded.  The pellet was suspended in 50ml 
suspension buffer containing 50mM tris-HCl (Fishers), 500mM NaCl, 10mM β-ME (beta 
mercaptoethanol Gibco  1mM PMSF (phenylmethyl sulphonyl fluoride Sigma-Aldrich, St. 
Loius, MO), lysozyme (0.2mg per ml; Sigma-Aldrich, St. Loius, MO), Triton X-100 
(10%,sigma)), and benzonase® nuclease(8 units per ml; Novagen, Madison, WI).  After brief 
sonication, the suspension was re-centrifuged, supernatant was harvested, and the pellet was 
re-suspended in 50ml double deionized water containing 0.1% Triton X-100 (Sigma-Aldrich, 
St. Loius, MO) and 10mM β-ME.  SDS-PAGE was performed to determine if the expressed 
protein was present in the supernatant or inclusion bodies.  Results indicated PCV capsid 
proteins were present in the pellet as inclusion bodies.  Recombinant PCV capsid protein was 
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recovered by re-suspending the pellet in buffer containing 10mM tris-HCl, 100mM 
NaH2PO4, 6M guanidine hydrochloride, 10mM β-ME and 1mM PMSF.  The mixture was 
rotated at room temperature for 30min after which the solution was centrifuged at 31,000 x g 
for 15 min at 4°C.  Recombinant PCV capsid proteins were purified by Ni-NTA agarose 
bead affinity chromatography (Qiagen®, Valencia, CA) according to manufacturer’s 
instructions.  Purified recombinant protein was analyzed by SDS-PAGE to determine the 
purity and concentration was measured by Bradford assay according to manufacturer’s 
instructions using a spectrophotometer.  The purified protein (more than 90% pure based on 
SDS-PAGE) was stored in -80°C. 
Oral fluid anti-PCV2 IgM-, IgG-, IgA-specific antibody quantification          Oral fluid 
samples were assayed in duplicate for anti-PCV2 IgM, IgA, and IgG immunoglobulins using 
indirect ELISAs specific for each isotype.  Plates were prepared by diluting PCV2 
nucleocapsid proteins in carbonate buffer (15mM NaCO3, 35 mM NaHCO3, pH 9.6) to a 
concentration of 2 ug per ml.  Antigen concentration of 200ug per well was achieved by 
transferring 100ul of the protein solution to each well of a 96 well plate (COSTAR 3590, 96 
well EIA/RIA plate, Corning, NY) and incubating the plate overnight at 4°C.  Plates were 
washed 3 times with 1X phosphate buffered saline and 0.05% Tween20® (PBST, pH 7.4).  
The last wash remained in the wells for 5 min at room temperature before the plate was 
aspirated and blotted dry.  To prevent non-specific binding, blocking buffer (5% Non-Fat 
Dry Milk (NFDM) in PBST, pH 9.6) was added to the plates and incubated at room 
temperature for 2 hr.  The plates were then washed as previously described.  Oral fluid 
samples were diluted 1:3 in 5% NFDM and 1% sodium azide in PBST and 100ul of diluted 
sample was incubated on the plates for 18 hr at 4°C.  Each antibody isotype ELISA used a 
horseradish-peroxidase conjugated secondary antibody specific for swine IgM, IgA, or IgG 
(E100-102, E100-104, E100-100, Bethyl Laboratories, Inc., Montgomery, TX).  The 
secondary antibody for each assay was diluted 1:25,000 with 5% NFDM in PBST and 100ul 
was added to each well and incubated for 2 hr at room temperature.  Next, 100ul of enzyme 
substrate solution at room temperature (TMB Peroxidase Substrate System, Kirkegaard & 
Perry Laboratories, Inc., Gaithersburg, MD) was added to each well and incubated at room 
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temperature for 20 min.  At precisely 20 min, 100ul of stop solution (1M phosphoric acid) 
was added to each well.  The plates were read at 450nm and results expressed as raw OD 
values. 
 Statistical methods 
Two-way analysis of variance (ANOVA) was performed (JMP® 8.0, SAS, Cary, NC) on 
log10 transformed data to test for significant differences among treatment groups.  Time and 
treatment were included as fixed effects in the model.  Thereafter, differences in treatment 
effects were analyzed using pair-wise comparisons with Tukey adjustment to account for 
Type 1 errors associated with multiple comparisons.  In all analyses, significance was 
defined as p  ≤  0.05.  All figures were generated using Sigmaplot® 11.0.0.75 (Systat 
Software Inc., San Jose, California)  
Results 
Oral fluid PCR 
Overall, 56 of 57 oral fluid samples from PCV2-inoculated pens were PCR positive through 
the observation period and 19 of 19 oral fluid samples from the negative control pen tested 
PCR negative.  This corresponded to a diagnostic sensitivity and diagnostic specificity of 
98% (95% CI: 94.8, 100.0) and 100%, respectively.  Two-way ANOVA analysis of PCR 
results showed significant differences in PCR log10 genomic copies per ml by DPI and 
treatment, but pair-wise comparisons found no significant differences between inoculated 
groups.  All pens were PCV2 positive by two DPI and all groups continued to shed PCV2 in 
oral fluids through the end of the collection period (Figure 1). 
ELISA     
PCV2 Serum IgG antibody ELISA          Two-way ANOVA analysis of serum IgG results 
showed that there were significant differences in S/P values by DPI and treatment.  Pair-wise 
comparisons detected no significant differences between inoculated groups.  Based on the 
0.30 cut-off of the PCV2 serum ELISA, the means of all inoculated groups indicated sero-
conversion between 14 and 21 DPI and thereafter a high level of serum IgG was maintained 
throughout the duration of the study (Figure 2).   
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Oral fluid antibody ELISA’s         Two-way ANOVA analysis of oral fluid IgG results 
showed significant differences in S/P values by DPI and treatment.  Pair-wise comparisons 
detected no significant differences in oral fluid IgG results (means shown in Table 2).  The 
onset of anti-PCV2 IgG in oral fluid was between 14 and 21 DPI and IgG remained 
detectable through the end of the study.  The means of the inoculated pens and the negative 
control pen over-time are shown in Figure 3. 
Two-way ANOVA analysis of oral fluid IgM results showed significant differences in S/P 
values by DPI and treatment.  Pair-wise comparisons showed that the level of IgM was 
significantly different among inoculation groups (means shown in Table 2), but changes in 
oral IgM concentrations did not coincide with re-inoculation events.  In inoculated groups, 
the onset of anti-PCV2 IgM  in oral fluid was between 10 and 14 DPI and IgM remained 
detectable through the end of the study.  The means of the inoculated pens and the negative 
control pen over-time are shown in Figure 4.   
Two-way ANOVA analysis of oral fluid IgA results showed significant differences in OD 
values by DPI and treatment.  Pair-wise comparisons indicated no significant differences in 
the amount of anti-PCV2 IgA in oral fluid samples (Table 2).  The onset of  anti-PCV2 IgA 
in oral fluid was between 14 and 21 DPI and IgA remained detectable through the end of the 
study.  The means of the inoculated pens and the negative control pen over-time are shown in 
Figure 5. 
Discussion 
The use of oral fluid specimens in diagnostic medicine is supported by a broad foundation of 
research and application in human medicine.  Both PCR- and antibody-based assays using 
oral fluids have been employed in the diagnosis of a variety of human pathogens, e.g., HIV, 
hepatitis A, B, and C viruses, measles, mumps, and others (Madar et al., 2003).  A diagnostic 
approached based on oral fluid specimens has facilitated the collection of large amounts of 
epidemiological data, e.g., HIV in Africa (Connolly et al., 2004; Fylkesnes and Kasumba, 
1998) and Thailand (Frerichs et al., 1994), and measles in Europe (Ramsay et al., 1997), 
Ethiopia (Nigatu et al., 2008), Brazil (de Azevedo Neto et al., 1995; Oliveira et al., 1998), 
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and Africa (Ohuma et al., 2009).   
In swine, a number of viral pathogens may be detected in oral fluid, including influenza virus 
(Heinen et al., 2001), PCV2 (Prickett et al., 2008b; Shibata et al., 2003), PRRSV (Prickett et 
al., 2008a,b; Wills et al., 1997), and vesicular stomatitis virus (Stallnecht et al., 1999).  
Likewise, antibodies against a variety of swine pathogens have been reported in oral fluid, 
e.g., Actinobacillus pleuropneumoniae (Loftager et al., 1993), E. coli (Duysscher and 
Dubois, 1978), classical swine fever virus (Corthier, 1976; Corthier and Aynaud, 1977), and 
transmissible gastroenteritis virus (Duysscher and Berman, 1980).   
The objective of this research was to provide improved estimates of the onset, level, and 
duration of PCV2 and anti-PCV2 antibody in oral fluid samples from experimentally 
inoculated pigs.  Anti-PCV2 antibodies (IgG, IgM, and IgA) were demonstrated in oral fluid 
from experimentally inoculated pigs from 14 to 98 DPI, but the small number of pens in the 
study precluded a robust statistical analysis of assay performance and cut-off selection.   
Shibata et al. (2003) previously reported the detection of PCV2 at 70 DPI in serum, feces, 
nasal, and oropharyngeal secretions from gnotobiotic pigs.  The current work expanded the 
previously reported period of shedding and showed that prolonged shedding of PCV2 in oral 
fluid is not restricted to gnotobiotes.  That is, PCV2 was detected by PCR in oral fluid 
samples from all pens of inoculated pigs at 2 DPI, i.e., the first sampling point.  Thereafter, 
PCV2 was detected in oral fluid samples from all inoculated pens throughout the remainder 
of the study.  At the final sampling point (DPI 98), the mean virus concentration in oral fluid 
was 1 x 105.6 genomic copies per ml.  Overall, the data indicated that PCV2 infection in 
swine populations can be efficiently monitored using oral fluid specimens.   
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Tables and Figures 
 
Table 1. Experimental design: inoculation schedule and PCV2 strains 
 Day Post Inoculation 
Group designation 0 35 70 
(1) Neg. Controls (n=6) --- --- --- 
(2) PCV2a (n=6) PCV2aA --- --- 
(3) R-PCV2a (n=6) PCV2aA  PCV2aA PCV2aA 
(4) R-PCV2a/b (n=6) PCV2aA PCV2bC  PCV2aB  
 
A Strain 40895 
B Strain 4838 
C Strain PVG4072 
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Table 2. Oral fluid ELISA: significant differences in ELISA S/P results by inoculation group 
Oral fluid ELISA: pair-wise comparisons* 
Group IgG IgM IgA 
(1) Controls (n=6) 0.09 (B) 0.05 (C) 0.06 (B) 
(2) PCV2a (n=6) 0.88 (A) 0.09 (B) 1.23 (B) 
(3) R-PCV2a (n=6) 1.20 (A) 0.15 (A) 1.53 (B) 
(4) R-PCV2a/b (n=6) 0.99 (A)   0.12 (AB) 1.29 (B) 
 
* Means not connected by the same letter are significantly different.  
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Figure 1. Mean log10 PCV2 genomic copies per ml in oral fluid over time  
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Figure 2. Mean PCV2 serum IgG ELISA S/P results over time  
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Figure 3. Mean PCV2 oral fluid IgG ELISA S/P results over time  
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Figure 4. Mean PCV2 oral fluid IgM ELISA S/P results over time  
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Figure 5. Mean PCV2 oral fluid IgA ELISA S/P results over time  
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GENERAL CONCLUSIONS 
The U.S. swine industry has experienced dramatic change over the past several decades 
marked by intense consolidation of pig production.  The U.S. Census of Agriculture numbers 
showed that the average total inventory among U.S. swine operations in 1959 was 37 animals 
(USDA, 1997).  This increased to a mean of 81 per operation in 1969, 130 in 1978, 215 in 
1987, 301 in 1992, and the trend continues today.  Historically, medication of individual 
animals prevailed in health management, with sporadic outbreaks of disease controlled with 
vaccination or depopulation-repopulation.  These measures were generally effective because 
small herd size was amenable achieving herd immunity, thereby limiting the severity and 
frequency of outbreaks.  
Health challenges have drastically changed as a result of the increased population size of 
production units, but changes in health management have lagged behind.  An important, but 
generally unrecognized, effect of this change is the impact of increasing herd size on the 
expression of clinical disease.  In today's high density production systems, pathogens that 
were previously economically and clinically unimportant have exerted a larger impact on 
health as a consequence of changing disease ecology.  While experimental research has 
provided information regarding the effects of co-infections on swine health, these research 
models cannot recreate the diversity or magnitude of co-infections that drive the ecological 
relationships among the pathogens that circulate in modern swine populations.  The 
economic burden of disease on pork producers is already significant, but will be exacerbated 
in the future by increasing energy and feed costs.  This fact drives the necessity to improve 
the health management of swine populations to protect swine health and enterprise 
profitability.   
To reduce the economic burden of disease and improve health management of herds, it is 
imperative to quantify the cost of specific pathogens and co-infection to compromised pig 
performance and the benefit of interventions in terms of return on investment.  The data to 
answer these questions can only be collected from commercial swine herds.  Historically, the 
estimates of the burden of infection have been based on analysis of serum samples collected 
from individual animals.  However, these data are cost-prohibitive because of the labor and 
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number of samples required to sufficiently represent the population.  
The research presented in this dissertation is the first foray into the surveillance of swine 
pathogens with pen-based oral fluid samples and there are many issues yet to be addressed.  
For example, it would be highly beneficial to devise a method to collect oral fluid samples 
from individual animals.  These data would make it possible to quantify the variability of 
antibody/pathogen shedding among individual animals. Oral fluid testing of individual 
animals would also have applicability in the swine industry, i.e., intensive disease monitoring 
of boar studs could benefit from an easy to collect and reliable diagnostic sample. 
Thus, the results of the research presented in this dissertation begin to lay the foundation for 
a new approach to field research in the area of swine health.  Although much work remains to 
be done, the review of the literature presented in chapter one and the supporting data in 
chapters two to five suggest that oral fluid sampling in swine populations holds the potential 
to be a powerful method of obtaining the data crucial to improving the health management of 
herds.   
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